Method for managing pain
Patent Information
- Application Number
- JP2024103068
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-07-13
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-26
AI Technical Summary
Current treatments for chronic pain, such as local anesthetics and opioids, are inadequate and associated with significant adverse effects, leading to a need for alternative therapies that provide analgesia without the drawbacks of opioid use.
Administration of expression vectors encoding carbonic anhydrase 10 (CA10), carbonic anhydrase 11 (CA11), or carbonic anhydrase 8 (CA8) fragments, such as CA8-204, to inhibit ITPR1 activation and intracellular calcium release, using viral vectors like adeno-associated virus (AAV) or herpes simplex virus (HSV) to target somatosensory nerves.
The method provides effective analgesia in chronic neuropathic and inflammatory pain models while minimizing motor and sensory interference, reducing the need for opioids and avoiding adverse effects.
Abstract
Description
[Technical field]
[0001] Grant Disclosure This invention was made with United States Government support under Grant No. DE022903 awarded by the National Institutes of Health. The United States Government has certain rights in this invention.
[0002] The present invention relates to materials and methods for treating or preventing pain.
[0003] Incorporation by Reference of Electronically Submitted Materials This application contains a sequence listing in computer readable form (Filename: 51774A_Seqlisting.txt, Size: 73,7002 bytes, Created on July 13, 2018), which is incorporated by reference in its entirety as a separate part of this disclosure. [Background technology]
[0004] Persistent pain costs approximately $650 billion annually in health care costs and lost productivity. The 2012 U.S. National Health Survey estimated that nearly 50 million American adults suffer from severe chronic or severe pain. The official position of the American Pain Society on August 18, 2015 was found at americanpainsociety.org / about-us / press-room / nih-study-shows-prevalence-of-chronic-or-severe-pain-in-us-adults. Other studies suggest that the burden of pain is greater.
[0005] Currently available chronic pain treatments are associated with disadvantages that leave most patients inadequately treated. For example, current local anesthetics are short acting with complete sensory and motor blockade resulting in immobility. Opioid drugs, including morphine, are the primary treatment for, for example, post-operative and chronic pain conditions. Long-term opioid use in treating chronic non-cancer pain has increased dramatically over the past few decades, with opioid abuse, tolerance and dependence being major public health concerns. Indeed, the side effects of opioid administration (e.g., tolerance, drug dependence / addiction, respiratory depression, constipation, nausea, pruritus, sedation, mood swings) limit the therapeutic potential of opioids, and the lack of suitable alternatives has led to an epidemic of opioid overuse, abuse and life-threatening complications. In the United States, prescription costs for opioid abuse alone were estimated at approximately $55.7 billion in 2007. Nearly half of these costs were workplace costs (e.g., lost productivity), 45% were medical costs (e.g., abuse treatment), and 9% were criminal justice costs. Birnbaum et al.,Pain medicine 2011;12:657-67.
[0006] Despite a significant amount of research focused on pain medication, there remains a need for treatment options that provide pain relief while minimizing (or avoiding) the adverse effects associated with opioid use. Summary of the Invention [Means for solving the problem]
[0007] The present disclosure provides a method for treating or preventing pain in a subject (e.g., human) in need thereof. In one embodiment, the method comprises administering to the subject an expression vector (e.g., a viral vector, such as an adeno-associated virus vector or a herpes simplex virus vector) comprising a nucleic acid sequence encoding carbonic anhydrase 10 or carbonic anhydrase 11, so that the nucleic acid is expressed to produce carbonic anhydrase 10 or carbonic anhydrase 11. Alternatively, the expression vector (e.g., a viral vector, such as an adeno-associated virus vector or a herpes simplex virus vector) comprises a nucleic acid sequence encoding carboxyl anhydrase 8 or carbonic anhydrase 8 fragment. Human and mouse versions of carbonic anhydrase are contemplated (CA8 / Car8, CA8 / Car8 fragment, CA10 / Car10 and / or CA11 / Car11). It will be appreciated that the description herein of the human version of carbonic anhydrase (e.g., CA8, CA8 fragment, CA10, and / or CA11) also applies to the mouse version (Car8, Car8 fragment, Car10, and / or Car11). The nucleic acid sequence encoding a fragment of carbonic anhydrase 8 (CA8 human or Car8 mouse) comprises (or consists essentially of, or consists of) the first three exons of the carbonic anhydrase 8 coding sequence. Optionally, the nucleic acid sequence encoding a fragment of carbonic anhydrase 8 is the alternative transcript CA8-204, which comprises the first three exons with an extended exon 3 and a retained intron. In various embodiments, the carbonic anhydrase is an antagonist of ITPR1 activation (pITPR1) and ITPR1-mediated intracellular calcium release.
[0008] In various embodiments, the pain is neuropathic pain, cancer pain, or inflammatory pain. In various embodiments, the method comprises administering the expression vector to the dorsal root ganglion of the subject, or administering the expression vector via intra-articular injection, intradermal delivery, or buccal delivery.
[0009] The foregoing summary is not intended to define all aspects of the invention, and additional aspects are described in other sections, such as the detailed description. It is understood that the entire document is intended to relate as a unified disclosure, and that all combinations of features described herein are contemplated, even if the combinations of features are not found together in the same sentence, or paragraph, or section of this document. Furthermore, the invention includes, as additional aspects, all embodiments of the invention narrower in scope than the variations specifically mentioned above. With respect to aspects of the invention described or claimed with "a" or "an," these terms are understood to mean "one or more," unless the context clearly demands a more limited meaning. With respect to elements described as one or more in a set, it is understood that all combinations within the set are contemplated. When an aspect of the invention is described as "comprising" a feature, it is also contemplated that the embodiment "consists of" or "consists essentially of" the feature.
[0010] The applicant(s) have invented the full scope of the claims appended hereto, but the claims appended hereto are not intended to encompass within their scope the prior art of others. Thus, if statutory prior art within the scope of a claim is brought to the applicant's attention by the Patent Office, or by any other entity or individual, the applicant(s) reserve the right to exercise amendment rights under the applicable patent law to redefine the subject matter of such claim to specifically exclude such statutory prior art or obvious variations of the statutory prior art from the scope of such claim. Variations of the invention defined by such amended claims are also contemplated as aspects of the invention. Additional features and variations of the invention will be apparent to those skilled in the art from the entirety of this application, and all such features are contemplated as aspects of the invention. [Brief description of the drawings]
[0011] [Figure 1A]Bar graphs showing relative pITPR1 density (Figure 1A), relative V5 density (Figure 1B), and relative pITPR1 density (Figure 1C). Overexpression of Car10 / CA10 in HEK293 cells inhibits forskolin-induced ITPR1 phosphorylation (pITPR1). HEK293 cells were transfected with AAV-V5 vectors expressing mouse (Car10) and human (CA10). Western blot analysis demonstrates that forskolin increases pITPR1 levels in a dose-dependent manner (Figure 1A). After transfection of V5-Car10 and V5-CA10 vectors, overexpression of CA10 and Car10 proteins was demonstrated using the V5 tag in Western blotting (Figure 1B). Overexpression of Car10 and CA10 reduced the phosphorylation of ITPR1 in response to 1 micromolar forskolin stimulation in HEK293 cells (Figure 1C). N=6, data presented as mean±standard error of the mean **P<0.01, ***P<0.001, one-way ANOVA. [Figure 1B] Bar graphs showing relative pITPR1 density (Figure 1A), relative V5 density (Figure 1B), and relative pITPR1 density (Figure 1C). Overexpression of Car10 / CA10 in HEK293 cells inhibits forskolin-induced ITPR1 phosphorylation (pITPR1). HEK293 cells were transfected with AAV-V5 vectors expressing mouse (Car10) and human (CA10). Western blot analysis demonstrates that forskolin increases pITPR1 levels in a dose-dependent manner (Figure 1A). After transfection of V5-Car10 and V5-CA10 vectors, overexpression of CA10 and Car10 proteins was demonstrated using the V5 tag in Western blotting (Figure 1B). Overexpression of Car10 and CA10 reduced the phosphorylation of ITPR1 in response to 1 micromolar forskolin stimulation in HEK293 cells (Figure 1C). N=6, data presented as mean±standard error of the mean **P<0.01, ***P<0.001, one-way ANOVA. [Figure 1C]Bar graphs showing relative pITPR1 density (Figure 1A), relative V5 density (Figure 1B), and relative pITPR1 density (Figure 1C). Overexpression of Car10 / CA10 in HEK293 cells inhibits forskolin-induced ITPR1 phosphorylation (pITPR1). HEK293 cells were transfected with AAV-V5 vectors expressing mouse (Car10) and human (CA10). Western blot analysis demonstrates that forskolin increases pITPR1 levels in a dose-dependent manner (Figure 1A). After transfection of V5-Car10 and V5-CA10 vectors, overexpression of CA10 and Car10 proteins was demonstrated using the V5 tag in Western blotting (Figure 1B). Overexpression of Car10 and CA10 reduced the phosphorylation of ITPR1 in response to 1 micromolar forskolin stimulation in HEK293 cells (Figure 1C). N=6, data presented as mean±standard error of the mean **P<0.01, ***P<0.001, one-way ANOVA.
[0012] [Diagram 2] Figure 1 is a bar graph showing that overexpression of AAV-V5-Car10 and AAV-V5-CA10 in HEK293 cells inhibited 1 μM ATP-induced cytoplasmic calcium release (y-axis) as indicated by Fura-2 (340 / 380 ratio). Calcium imaging data demonstrated that overexpression of car10 and CA10 proteins inhibited 1 μM ATP-induced cytoplasmic calcium release in HEK293 cells when compared to empty vector controls. Overexpression of car10 and CA10 significantly inhibited free calcium release (P<0.001). N=4 coverslips and a total of 200 cells per sample. **P<0.01, ***P<0.001 by two-way ANOVA followed by Bonferroni test.
[0013] [Diagram 3]Bar graphs showing paw withdrawal latencies (seconds) (y-axis) on various test days (x-axis) demonstrating that gene transfer of V5-Car10 and V5-CA10 results in suppression of heat hyperalgesia in the carrageenan inflammatory pain mouse model. Thermal responses after overexpression of V5-Car10 and V5-CA10 via sciatic nerve injection of saline, AAV8-none, AAV8-V5-Car10 viral particles and AAV8-V5-CA10 viral particles (1.06E14 viral particles and 1.66E14 viral particles, respectively) in C57BL / 6J mice. Basal thermal latencies were increased for 15 days after injection of AAV8-V5-Car10 viral particles and AAV8-V5-CA10 viral particles, but not after saline or after viral particles containing empty vector. After injection of carrageenan at the end of 16 days, saline and AAV8-free viral particles showed significant reductions from baseline thermal latency, whereas AAV8-V5-Car10 and AAV8-V5-CA10 groups were not different from baseline (N=8. *P<0.05, **P<0.01, ***P<0.001 by two-way ANOVA followed by Bonferroni post-hoc test).
[0014] [Figure 4]Bar graphs showing paw withdrawal latencies (seconds) (y-axis) on various test days (x-axis) demonstrating that gene transfer of V5-Car10 and V5-CA10 results in suppression of heat hyperalgesia in a complete Freund's adjuvant (CFA) chronic inflammatory pain mouse model. Thermal responses after sciatic nerve injection of saline, AAV8-none, AAV8-V5-Car10 viral particles, and AAV8-V5-CA10 viral particles (1.06E14 viral particles and 1.66E14 viral particles, respectively). Basal thermal latencies increased for 15 days after injection of AAV8-V5-Car10 viral particles and AAV8-V5-CA10 viral particles, but not after saline or after viral particles containing an empty vector. After CFA injection at the end of day 16 (when thermal latencies were measured), there was a significant reduction from baseline in all groups. Starting at day 24, AAV8-V5-Car10- and AAV8-V5-CA10-injected groups showed analgesia (fever latencies above baseline, similar to 15 and 16 days after virus injection), whereas the control group was unchanged from before CFA injection (N=8. *P<0.05, **P<0.01, ***P<0.001 by two-way ANOVA followed by Bonferroni post-hoc test).
[0015] [Diagram 5]Bar graphs showing paw withdrawal latencies (seconds) (y-axis) on various test days (x-axis), demonstrating that gene transfer of V5-Car10 and V5-CA10 prevents mechanical hyperalgesia in the neuropathic (Chung) mouse pain model. Mechanical withdrawal thresholds after sciatic nerve injection of saline, AAV8-none, AAV8-V5-Car10 viral particles, and AAV8-V5-CA10 viral particles (1.06E14 viral particles and 1.66E14 viral particles, respectively) in C57BL / 6J mice. AAV8-V5-Car10 increased mechanical withdrawal thresholds (analgesia) above baseline 12 days after viral injection, which was maintained until 22 days after, despite spinal nerve ligation 19 days later. There was no similar increase in withdrawal threshold in other groups. (N=8. *P<0.05, **P<0.01, ***P<0.001 by two-way ANOVA followed by Bonferroni test).
[0016] [Figure 6] 1 is a bar graph showing the relationship between paw withdrawal latency (seconds) (y-axis) approximately 30 minutes after morphine was given (ip) (x-axis). The increase was significant at doses of 10, 30, and 60 mg / kg when compared to saline.
[0017] [Figure 7] Graph showing the relationship between paw withdrawal latency (seconds) (x-axis) and morphine equivalent oral dose (intraperitoneal administration assessed approximately 30 min after administration, data are extrapolated to human equivalent dosing using allometric conversion) (y-axis) in a 60 kg human. Prolongation of paw withdrawal latency following transfer of V5-Car10 and V5-CA10 produces significant analgesia in these mouse models when compared to the human oral equivalent dose, as described in Figures 2-5.
[0018] [Figure 8] 9 is the amino acid sequence encoding CA10.
[0019] [Figure 9]12 is a nucleotide sequence encoding CA10-203.
[0020] [Figure 10] 13 is a nucleotide sequence encoding the CA8 fragment, CA8-204 (SEQ ID NO:13).
[0021] [Figure 11] Bar graphs showing paw withdrawal latencies (seconds) (y-axis) on various test days (x-axis) demonstrating the analgesic effect of expression of V5-CA8WT (left bar = CA8WT after spinal nerve ligation, right bar = CA8WT after spinal nerve ligation) and V5-CA8MT (CA8MT represents an S100P point mutation that destabilizes the protein, resulting in rapid degradation by the proteasome; Turkmen S, et al., PLoS Genet 5, e1000487) (middle bar = CA8MT after spinal nerve ligation) in the neuropathic (Chung) mouse pain model. Mechanical withdrawal thresholds after sciatic nerve injection of AAV viral particles (approximately 1.0 x 1014 viral particles) in C57BL / 6J mice are shown. AAV8-V5-CA8WT increased mechanical withdrawal thresholds above baseline (analgesia) for 7 days after administration and was maintained for up to 38 days despite spinal nerve ligation 3 days later. There was no similar increase in withdrawal thresholds after administration of expression vectors encoding AAV8-V5-CA8MT. (N=8. *p<0.05, **p<0.01, ***p<0.001 by two-way ANOVA followed by Bonferroni test). The results of this study are surprising. First, it was unclear whether CA8 functions on the mouse ITPR1 target. These data indicate that the human protein functions in mouse cells / tissues and that the pharmacodynamic properties of CA analgesic peptides and variants can be examined using the in vitro bioassays described herein. Furthermore, neuropathic pain is thought to arise from a different mechanism than inflammatory pain. Moreover, drugs that act well on inflammatory pain do not produce antihyperalgesia or antiallodynia in neuropathic pain models. Surprisingly, CA8 is effective in preventing and treating neuropathic pain.
[0022] [Figure 12A] 1 is a bar graph showing gene expression of CA8 fragments encoded by the first three exons of the CA8 coding sequence, i.e., alternative splice fragment "CA ALT G" (the "G" allele at SNP rs6471859), and wild-type CA8 "CA ALT C" (the C allele for SNP rs6471859), as measured by quantitative PCR in NBL cells. Wild-type CA8 normally splices, and NBL cells produce this fragment encoded by the first three exons of CA8 almost exclusively. Expression of the "G" allele at SNP rs6471859 results in alternative splicing, and CA8-204 products with intron-retained extended exon 3 are almost completely undetectable in NBL cells. Thus, essentially all CA8 transcripts and protein fragments encoded by the first three exons of CA8 are produced and stable in NBL cells. [Figure 12B] 1 is a bar graph demonstrating that this CA8 fragment (encoded by only the first three exons) inhibits ATP-stimulated calcium release in NBL cells. Wild-type CA8 (C allele for SNP rs6471859) normally splices and this fragment of the wild-type gene product is produced in NBL cells. Expression of the "G" allele at SNP rs6471859 results in alternative splicing and production of CA8-204 protein is minimal in NBL cells. This fragment does not mediate inhibition in these cells compared to vector expressing CA8-201 (wild-type protein, left bar) or a vector expressing a truncated CA8 fragment generated by the "C" allele (right bar).
[0023] [Figure 13A]1 is a bar graph showing the expression of CA8 fragments in HEK293 as measured by quantitative PCR. Expression of the "G" allele at SNP rs6471859 results in alternative splicing in these cells, producing a CA8-204 product with an extended exon 3 with intron retention in HEK293 cells (left bar). There is essentially no detectable wild-type CA8 (C allele at SNP rs6471859) in HEK293 cells, and the cells produce a fragment corresponding to the first three exons of CA8. Thus, essentially all vector expression in HEK293 cells is the CA8-204 alternative transcript. [Figure 13B] 1 is a bar graph demonstrating that CA8-204 inhibits ATP-stimulated calcium release in HEK293 cells. A vector expressing the "G" allele at SNP rs6471859 results in alternative splicing and production of the CA8-204 protein, which is found in HEK293 cells and inhibits ATP-induced calcium release compared to vectors expressing wild-type CA8 (CA8-201) and vectors expressing the fragment encoded by the "C" allele.
[0024] [Figure 14] A diagram of an exemplary HSV expression vector for CA8 delivery. TrkAp-CA8-Flag, Nav1.7p-CA8-204-Flag, Nav1.8p-CA8-204-Flag, and (not shown) Tet-Advillin-CA8-204-Flag) cassettes can be integrated into the ICP4 locus. The basic vector is optionally deleted for ICP0, ICP4 IE regulatory gene, joint region, ICP27, ICP47, ICP22 IE gene "TAATGARAT", and UL41 vhs gene. A gB:N / T mutation may be present (enhancing cell entry in various embodiments), and a BAC sequence is located between loxP sites in the intergenic region. The vector construct is also suitable for delivery of CA8 fragments.
[0025] [Figure 15] Diagram of an exemplary HSV expression vector for CA8 delivery. TrkAp-CA8-Flag, Nav1.7p-CA8-Flag, Nav1.8p-CA8-Flag, and (not shown) Tet-Advillin-CA8-Flag cassettes can be integrated into the ICP4 locus. The basic vector has ICP0, ICP4 IE regulatory genes, joint region, ICP27, ICP47, ICP22 IE gene "TAATGARAT", and UL41 vhs gene deleted. gB:N / T mutations enhance cell entry, and the BAC sequence is located between loxP sites in the intergenic region.
[0026] [Figure 16] Diagram of an exemplary HSV expression vector for CA10 biotherapeutic delivery. Diagram of TrkAp-CA10-Flag, Nav1.7p-CA10-Flag, Nav1.8p-CA10-Flag, and (not shown) Tet-Adovillin-CA10-Flag cassettes can be integrated into the ICP4 locus. The basic vector has ICP0, ICP4 IE regulatory genes, joint region, ICP27, ICP47, ICP22 IE gene "TAATGARAT", and UL41 vhs gene deleted. gB:N / T mutations enhance cell entry, and BAC sequences are located between loxP sites within the intergenic region.
[0027] [Figure 17] Diagram of an exemplary HSV expression vector for CA11 delivery. Also, TrkAp-CA11-Flag, Nav1.7p-CA11-Flag, Nav1.8p-CA11-Flag, and (not shown) Tet-Advillin-CA11-Flag cassettes representing inducible promoter systems can be integrated into the ICP4 locus. The basic vector has deleted ICP0, ICP4 IE regulatory genes, joint region, ICP27, ICP47, ICP22 IE gene "TAATGARAT", and UL41 vhs gene. gB:N / T mutations enhance cell entry, and BAC sequences are located between loxP sites in the intergenic region.
[0028] [Figure 18] Bar graph showing NGF-induced intracellular calcium release (y-axis) in NBL cells in response to various doses of NGF (1, 10, 100 ng / mL) (x-axis). HEK293 cells also respond to NGF with increased intracellular calcium release (data not shown).
[0029] [Figure 19] Bar graph showing that NGF-induced intracellular calcium release (y-axis) in NBL cells is nearly complete by overexpression of wild-type CA8, but not by overexpression of mutant CA8, and ATP-induced intracellular calcium release is inhibited by overexpression of CA10 (data not shown).
[0030] [Figure 20] Figure 1 shows a bar graph showing blockade of NGF-induced intracellular calcium release by the selective ITPR1 inhibitor 2-APB in NBL cells. Thus, NGF signaling in NBL cells is almost exclusively via ITPR1 and is almost completely inhibited by this ITPR1 selective inhibitor. Similar inhibition by 2-APB was also observed in HEK293 cells (data not shown).
[0031] [Figure 21A] Schematic diagram of the 5HT-3 receptor promoter and a comparison of the mouse sequence (SEQ ID NO: 14) and the human sequence (SEQ ID NO: 15) (Journal of Neuroscience 15, August 1998, 18(16)6186-6194).
[0032] [Figure 21B] The 5HT-3 receptor promoter sequence (SEQ ID NO:16) is provided.
[0033] [Figure 22]The sequence of the NPY-Y1 receptor promoter-exon 1A (SEQ ID NO: 17) is provided (JBC Vol. 270, No. 45, Issue of November 10, pp. 27272-27276, 1995).
[0034] [Figure 23] The sequence of the NPY-Y1 receptor promoter-exon 1B (SEQ ID NO: 18) is provided (JBC Vol. 270, No. 45, Issue of November 10, pp. 27272-27276, 1995).
[0035] [Figure 24] The sequence of the NPY-Y1 receptor promoter-exon 1C (SEQ ID NO: 19) is provided (JBC Vol. 270, No. 45, Issue of November 10, pp. 27272-27276, 1995).
[0036] [Figure 25A] The sequences of the mouse (SEQ ID NO:20), rat (SEQ ID NO:21) and human (SEQ ID NO:22) Nav1.8 promoter SCN10A are provided (J Neurochem. 2008 August;106(3):1209-1224).
[0037] [Figure 25B] 1 provides the sequence of the human Nav1.8 promoter SCN10A (SEQ ID NO:23).
[0038] [Figure 26] The sequence of the Nav1.7 promoter SCN9A (SEQ ID NO:24) is provided.
[0039] [Figure 27A] The sequence of the human Trk-A promoter (SEQ ID NO:25) is provided (J. Biol. Chem. 1998, 273:39-44). Potential DNA-binding protein binding sites are marked with boxes.
[0040] [Figure 27B] The sequence of the Trk-A promoter is provided (SEQ ID NO:26).
[0041] [Figure 28] The sequence of the advillin promoter (SEQ ID NO:27) is provided.
[0042] [Figure 29] The sequence of the CGRP receptor promoter (SEQ ID NO:28) is provided.
[0043] [Diagram 30] The sequence of the GRIN3A promoter (SEQ ID NO:29) is provided.
[0044] [Diagram 31] 1 is a graph showing that gene transfer of CA fragment CA8204C in an inflammatory pain animal model resulted in analgesic hyperplasia inhibition.
[0045] [Diagram 32] 1 is a graph showing that gene transfer of the CA fragment CA8204G in an inflammatory pain animal model resulted in analgesic hyperplasia inhibition.
[0046] [Diagram 33] 1 depicts a gel showing that RYR1 binds to CA10 (Car10) as demonstrated by immunoprecipitation (IP) and Western blotting (WB) detection.
[0047] [Figure 34A] 34A is a gel and provides a bar graph showing that Car10 and CA10 inhibited forskolin-induced pITPR1. Figure 34A provides the results for the untreated control (no forskolin). Figure 34B provides the results from treatment with 1 μM forskolin. [Figure 34B]34A is a gel and provides a bar graph showing that Car10 and CA10 inhibited forskolin-induced pITPR1. Figure 34A provides the results for the untreated control (no forskolin). Figure 34B provides the results from treatment with 1 μM forskolin.
[0048] [Diagram 35] 1 is a bar graph showing that expression of V5-Car10 and V5-CA10 in HEK293 cells inhibits ATP-induced cytoplasmic calcium release.
[0049] [Diagram 36] 1 is a bar graph showing that 5HT-induced RYR-dependent calcium release in NBL cells is inhibited by ryanodine.
[0050] [Figure 37] 1 is a bar graph showing that overexpression of V5-Car10 and V5-CA10 in NBL cells inhibits 50 μM 5HT-induced cytoplasmic calcium release.
[0051] [Figure 38] The structures of pCMV-N-flag-CA8-204G and pCMV N-flag-CA8-204C are shown.
[0052] [Figure 39] The structures of pAAV-flag-CA8-204G (ALT G) and pAAV-flag-CA8-204C (ALT C) are shown.
[0053] [Diagram 40] 1 shows CA8-204G inhibition of calcium release (Ca2+Fura2 imaging) in NBL cells.
[0054] [Figure 41A]Differential tissue expression of CA8 ALT(G) (CA8-204G) and CA8 ALT(C) (CA8-204C) in HEK293 cells (Figure 41A) and NBL cells (Figure 41B). [Figure 41B] Differential tissue expression of CA8 ALT(G) (CA8-204G) and CA8 ALT(C) (CA8-204C) in HEK293 cells (Figure 41A) and NBL cells (Figure 41B).
[0055] [Diagram 42] 1 is a graph showing that tissue expression of the CA8-204C and CA8-204G fragments is altered.
[0056] [Diagram 43] 1 shows that the CA8-204C fragment inhibits ATP-stimulated calcium release in NBL cells.
[0057] [Diagram 44] 1 is a gel showing that the CA8-204G or CA8-204C peptide fragment is 28 kDa or 26 kDa as selectively expressed in HEK293 cells or NBL cells.
[0058] [Diagram 45] 1 shows that CA8 204C inhibits forskolin-induced phosphorylation of pITPR1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0059] In various embodiments, the present disclosure relates to materials and methods that provide safe and effective analgesia. The present disclosure is the first to show that carbonic anhydrase 10 (CA10 (human) and Car10 (rodent)) produces analgesia and prevents hyperalgesia, for example, in chronic neuropathic and inflammatory pain models. In at least one embodiment, the materials and methods relieve pain while minimizing interference with motor and other sensory functions, thereby improving quality of life while minimizing the need for opioid use.
[0060] In one aspect, the present disclosure provides a method for treating or preventing pain in a subject in need of such treatment or prevention. The method comprises administering to the subject an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase 10 or carbonic anhydrase 11, so that the nucleic acid is expressed to produce carbonic anhydrase 10 or carbonic anhydrase 11 in the subject. In an alternative embodiment, the method comprises administering to the subject an expression vector comprising a nucleic acid sequence encoding a fragment of carbonic anhydrase 8, so that the nucleic acid is expressed to produce the fragment in the subject. The nucleic acid sequence encoding the fragment of carbonic anhydrase 8 comprises the first three exons of CA8, and optionally the nucleic acid sequence encoding the CA8 fragment is CA8-204 as described herein. In various embodiments, the expression vector is a viral vector, such as an adeno-associated virus vector or a herpes simplex virus vector.
[0061] Aspects of the present invention are further described below. The use of section headings is merely for ease of reading and is not intended to be limiting per se. It is to be understood that the entire document is intended to be considered as a unified disclosure and that all combinations of features described herein are contemplated.
[0062] Carbonic anhydrase Carbonic anhydrase 10 (CA10) is a member of the carbonic anhydrase (CA) supergene family and is one of three catalytically inactive CA isoforms. CA10 retains the central carbonic anhydrase motif but lacks catalytic zinc-coordinating residues important for enzymatic activity. The function of CA10 previously remained unclear. Sequence comparisons revealed 100% identity between the CA10 proteins of human (Homo sapiens), rat (Rattus norvegicus), and mouse (Mus musculus), as well as 90% identity at the amino acid level with zebrafish (Danio rerio). There are nine transcripts encoding human CA10, resulting in seven functional isoforms. The nucleic acid and amino acid sequences of human CA10 are set forth in Genbank accession numbers NM_020178 (SEQ ID NO: 3), NP_064563 (SEQ ID NO: 4), NM_001082534 (SEQ ID NO: 5), NP_001076003 (SEQ ID NO: 6), NM_001082533 (SEQ ID NO: 7) and NP_001076002 (SEQ ID NO: 8), and the amino acid sequence of human CA10 is also provided in UniProtKB Q9NS85 (SEQ ID NO: 9).
[0063] In various embodiments, the expression vector comprises a nucleic acid sequence encoding a peptide comprising at least 90% identity (e.g., at least 95% identity or 100% identity) to SEQ ID NO:2. In various embodiments, the expression vector comprises a nucleic acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) to SEQ ID NO:1. As used herein, "at least 90% identity" and similar terms include any integer between 90% and 100%, such as, for example, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. Additionally, the term "at least ¥[percentage] identity" includes any percentage equal to or greater than the number of identical nucleotides or amino acids divided by the total number of nucleotides or amino acids (¥[at least percentage identity] ≧ ¥[number of identical nucleotides or amino acids]] / ¥[total number of nucleotides or amino acids]). Calculation of the percent identity of aligned amino acids (or nucleotides) of two or more sequences is well understood in the art and is conventionally determined using known computer programs.For example, alignment of two or more sequences to determine percent sequence identity is optionally performed using the algorithm described by Altschul et al. (Nucleic Acids Res., 25:3389-402 (1997)) incorporated in the BLAST (basic local alignment search tool) program, available on the National Center for Biotechnology Information website.The gene product exhibits at least one carbonic anhydrase (CA10) activity, such as analgesia or antagonist of ITPR1 activation (pITPR1) and ITPR1-mediated intracellular calcium release.
[0064] Despite the considerable sequence divergence between CA8 and CA10, it is surprising that CA10 and Car10 exhibit the activities described herein (e.g., analgesia). The amino acid sequence of CA10 demonstrates the highest percent identity with CA11, along with an overall percent identity of 25-57% with other CA isozymes. Specifically, CA10 (NP_001076003.1) exhibits only about 33% identity with CA8 (NP_001308766.1) at the amino acid level. Indeed, CA10 is most similar to CA11 compared to CA8 or other family members at the amino acid level, with CA10 demonstrating 58% sequence identity with CA11 and 33% sequence identity with CA8. CA10 lacks two of the three zinc-ligand binding histidine residues, suggesting a lack of CA enzymatic activity. CA11 also lacks the zinc-ligand binding site, suggesting a lack of enzymatic activity. Similar to CA8, CA10 was found to inhibit forskolin-induced phosphorylation of ITPR1 (pITPR1), and ATP-induced ITPR1 mediated intracellular calcium release in HEK293 and NBL cells. CA8 is thought to be an allosteric inhibitor of IP3 ligand binding and activation of ITPR1, resulting in intracellular calcium release. Allosteric inhibition of ITPR1 activation was previously thought to depend on CA8 binding to ITPR1 (Hirota J, et al., Biochem J 372, 435-441). In contrast to CA8, CA10 and Car10 do not bind ITPR1 in isoelectric-western. Surprisingly, despite the lack of ITPR1 binding, CA10 / Car10 and CA8-204 inhibit ITPR1 activation (pITPR1) and ATP-induced intracellular calcium release, producing significant analgesia in vivo.
[0065] In various embodiments, the expression vector comprises a nucleic acid sequence encoding a CA8 fragment. The nucleic acid sequence comprises (or consists of) the first three exons of the CA8 (or Car8) coding sequence. Optionally, the nucleic acid sequence encoding the CA8 fragment is CA8-204, the sequence of which is provided herein in FIG. 10. In some embodiments, the CA8 fragment is CA8-204C, the nucleic acid sequence of which is set forth in SEQ ID NO: 32 (the amino acid sequence of which is set forth in SEQ ID NO: 30). In some embodiments, the CA fragment is CA8-204G, the nucleic acid sequence of which is set forth in SEQ ID NO: 33 (the amino acid sequence of which is set forth in SEQ ID NO: 31). In some embodiments, the CA-8 fragment is CA8-202 (SEQ ID NO: 34) or CA-203 (SEQ ID NO: 35). In various embodiments, the expression vector comprises a nucleic acid sequence having at least 90% identity (e.g., at least 95% or 100% identity) to the CA8-204 nucleic acid sequence described herein. As used herein, "at least 90% identity" and similar terms encompass any integer between 90% and 100%, such as, for example, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The nucleic acid sequence of a CA8 fragment containing exons 1-3 is provided as SEQ ID NO: 1. The nucleic acid sequence of a CA8 fragment containing exons 1-5 is provided as SEQ ID NO: 35. The nucleic acid sequence of a CA8 fragment containing exons 1-8 is provided as SEQ ID NO: 34. The nucleotide and amino acid sequences of CA11 are provided as SEQ ID NO: 10 and SEQ ID NO: 11. Expression products of any of the sequences described herein exhibit at least one carbonic anhydrase activity, such as analgesia or an antagonist of ITPR1 activation (pITPR1) and ITPR1-mediated intracellular calcium release.
[0066] The materials and methods description for CA8, CA10, and CA11 also applies to the mouse (the protein versions are Car8, Car10, and Car11, which are contemplated for use in various embodiments of the present disclosure.
[0067] Expression vector A "vector" or "expression vector" is any type of genetic construct that contains a nucleic acid (DNA or RNA) for introduction into a host cell. In various embodiments, the expression vector is a viral vector, i.e., a viral particle that contains all or part of a viral genome that can function as a nucleic acid delivery vehicle. A viral vector that contains an exogenous nucleic acid(s) encoding a gene product of interest is also referred to as a recombinant viral vector. As will be understood in the art, in some contexts, the term "viral vector" (and similar terms) may be used to refer to the vector genome in the absence of a viral capsid. Viral vectors for use in the context of this disclosure include, for example, retroviral vectors, herpes simplex virus (HSV)-based vectors, parvovirus-based vectors, such as adeno-associated virus (AAV)-based vectors, AAV-adenovirus chimeric vectors, and adenovirus-based vectors. All of these viral vectors are described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989); Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, NY (1994); Coen DM, Molecular Genetics of Animal Viruses in Virology, 2 ndStandard recombinant DNA techniques as described in the publication of the American Society of Clinical Oncology, Vol. 13, No. 1, 1992, pp. 1171-1175, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2101-2112, and references cited therein. Additionally, viral vectors can be prepared using large genomic coding sequences from humans and other host species, including entire genes with 5' and 3' regulatory sequences, using the application of homologous recombination-mediated cloning and manipulation of targeted genomic regions using Gateway cloning (Hartley et al., Genome Res 2000, 10:1788-1795) and / or "recombinant engineering" systems (Copeland et al., Nat Rev Genet 2001, 2:769-779).
[0068] In various embodiments, random or semi-random libraries are developed in which DNA encoding precursors of different carboxyl anhydrase peptides is provided. Such libraries can contain hundreds or more different sequences. In various aspects, thousands or more (at least 1000 or at least 10,000) different expression cassettes differing in the sequence of DNA encoding precursors of carboxyl anhydrase peptides constitute the library. Such libraries can be constructed by first generating a population of random or semi-random oligonucleotides encoding precursors of peptides with one or more desired characteristics (e.g., precursors of carboxyl anhydrase peptides similar to CA8, CA10 or CA11). This population of oligonucleotides can then be cloned into the cassette backbone (i.e., in frame with the preproprotein signal sequence and optional biomarker).
[0069] An example of a method for constructing random or semi-random libraries employs the GATEWAY™ stem (Invitrogen, Carlsbad, Calif.). In the GATEWAY™ system, ccdB is used as a negative selectable marker, which, if present, kills bacterial cells. ccdB is replaced by random or semi-random sequences through site-specific recombination carried out by a modified lambda integrase. In the GATEWAY™ technology, two bacterial strains are used: ccdB-sensitive and ccdB-resistant. A ccdB-containing plasmid is grown and purified in the ccdB-resistant bacteria. This plasmid is then used for in vitro recombination. The recombination products are transformed into ccdB-sensitive bacteria, which select for plasmids in which the ccdB gene has been replaced by the gene of interest during in vitro recombination. By replacing ccdB, the background of cloning and library construction is dramatically reduced or eliminated, allowing the free movement of genes in and out or various plasmids. As a starting point, the basic plasmid is grown in a bacterium that is resistant to the toxic effects of ccdB, for which a very limited number of genotypes of ccdB are available. To employ the GATEWAY™ technology in the context of this disclosure, a large viral vector system is used to engineer a bacterial strain suitable for transformation with large DNA (such as BACs) to express a gene that confers insensitivity to ccdB. The preferred strain is derived from the DH10B bacterial strain used in propagating and manipulating BACs, and also carries a mutation (fhuA::IS2) that increases the propensity for transformation with very large DNA.
[0070] In some embodiments, the viral vector is an HSV-based vector. HSV is an encapsulated icosahedral double-stranded DNA virus that infects mammals, including humans. Wild-type HSV infects and replicates in both terminally differentiated non-dividing and dividing cells. The advantage of HSV vectors is the ability of the virus to enter a latent stage, resulting in long-term DNA expression. In addition, HSV preferentially infects sensory nerves, often escaping immune surveillance, does not spread to the central / peripheral nervous system, and exhibits excellent retrograde transport (e.g., intradermal, intra-articular, or peripheral nerves). In addition, HSV allows for large genomic inserts using Gateway and / or recombinant engineering techniques. The sequence of HSV is available at ncbi.nlm.nih.gov:80 / entrez / query.fcgi?cmd=Retrieve&db=nucleotide&list_uid-s=9629378&dopt=GenBank&term=hsv-1&qty=1.
[0071] Optionally, the HSV vector is replication-defective, e.g., at least one HSV gene essential for replication or packaging is rendered nonfunctional (mutated or deleted). For example, the replication-defective HSV vector may lack one or more gene functions from the early, immediate early, or late regions of the HSV genome. In various embodiments, the HSV vector is "proliferation-defective", meaning that multiple gene functions essential for viral replication are disrupted. For example, the propagation-defective vector may lack gene functions from two or more of the early, immediate early, and late regions of the HSV genome. The HSV vector optionally lacks a functional immediate early gene selected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47, and any combination thereof, e.g., lacks functional ICP0, ICP4, ICP22, ICP27, and ICP47 genes (optionally rendered nonfunctional by deletion). Non-essential genes can also be removed from viral vectors, such as HSV vectors, to accommodate large pieces of foreign DNA. For example, HSV vectors may essentially lack the entire HSV genome.In this regard, vectors preferably include viral inverted terminal repeats (ITRs) and / or packaging signals, although these components are not required in all embodiments of the present disclosure.Optionally, one or more promoters or viral ITRs and packaging signals remain intact (i.e., HSV amplicon).
[0072] Nucleotides encoding CA10 (or Car10) or CA11 (or Car11) optionally replace sequences of deleted native viral genes (optionally rendering the vector replication-deficient). Nucleotides encoding CA8 (or Car8) or a CA8 fragment (or Car8 fragment) optionally replace sequences of deleted native viral genes (e.g., rendering the vector replication-deficient).
[0073] When HSV vectors become replication-deficient due to the deletion of multiple genome segments, they optionally contain spacer elements to provide viral growth in complementing cell lines similar to that achieved by single replication-deficient HSV vectors. Spacer elements can be of any desired length and can contain one or more sequences of any nucleic acid that encodes a desired analgesic carbonic anhydrase molecule. The sequence of the spacer element can be coded or non-coded with respect to the HSV genome, and can be native or non-native, but does not restore replication-essential function(s) to the deleted region. Furthermore, including spacer elements in any or all of the deleted HSV regions will reduce the capacity of the HSV vector for large inserts.
[0074] In various embodiments, the HSV vector is a replication-deficient HSV (rdHSV) vector that is functionally deleted for all IE genes. Benefits of deleting additional IE genes include, but are not limited to, reduced toxicity in neurons and other cell types. A representative vector backbone structure includes a transgene cassette inserted at two selected sites in the latency (LAT) locus, for example, protected against developmental silencing by resident insulator / chromatin boundary elements (CTRL or CTCF). These elements, together with the HSV LAP2 promoter, provide for long-term expression. The placement of ectopic insulators adjacent to a transgene cassette inserted in the viral UL50-UL51 intergenic region also enhances long-term transgene expression from this locus in primary human cells. As merely an example of a suitable vector system, growth of HSV vectors to high titers has been demonstrated using an ICP4 / ICP27 / Cre-expressing U2OS cell line, where Cre recombination removes the inhibitory BAC sequences present in the vector construct.
[0075] It should be understood that the deletion of different regions of HSV vector can change the immune response of the host.In particular, the deletion of different regions can reduce the inflammatory response caused by HSV vector.In addition, the protein coat of HSV vector can be modified to reduce the ability or inability of HSV vector to be recognized by neutralizing antibodies against wild-type protein coat.
[0076] The basic vector, complementing cells, and engineering techniques can generate safe vectors for long-term expression of CA10 (or Car10), CA11 (or Car11), CA8 (or Car8), and / or CA8 fragments (or Car8 fragments) to promote analgesia from the following promoters in the Gateway transfer plasmid: sensory neuron-specific Nav1.8 (e.g., sodium channel), neuron-specific Nav1.7 (e.g., sodium channel), high affinity nerve growth factor receptor (TrkA), somatosensory-specific advillin CA8 driver, and non-specific constitutive CMV promoter. Inducible promoter sequences, such as tetracycline-responsive promoters, are also appropriate in the context of this disclosure. Advantages of using HSV vectors to deliver human therapeutics include well-defined tissue specificity, lack of immune response, and lack of potential reactivation, even in immunocompromised hosts.
[0077] In various embodiments, the HSV vector comprises the HSV latency-associated transcript (LAT) insulator.
[0078] For HSV-based vectors, see, e.g., U.S. Pat. Nos. 5,837,532, 5,846,782, 5,849,572, and 5,804,413, and International Patent Publication Nos. WO91 / 02788, WO96 / 04394, WO98 / 15637, and WO99 / 06583, which are incorporated by reference in their entireties.
[0079] An example of an HSV vector for use in the context of the present disclosure comprises an extended ICP4 or ICP27 deletion, preferably both. An "extended" deletion means that the HSV vector does not contain homologous sequences at either or both of the loci of the homologous sequences compared to the complementing cell line used to produce the homologous sequences. Desirably, the virus does not have any coding or promoter sequences of ICP4 or ICP27 (or both). Preferably, the deletion of ICP27 also extends to the UL55 locus, desirably both genes are deleted. Thus, the virus for use in the context of the present disclosure comprises an extended deletion in these genes, such that there is no viral homology to the ICP4, ICP27 and UL55 genes used in the complementing cell line. Desirably, the vector does not contain any homologous DNA sequences to those employed in the complementing cell line (e.g., even using different regulatory and polyadenylation sequences).
[0080] It will be understood that in the context of the present disclosure, vectors other than HSV-based vectors can be used.For example, adenovirus, adeno-associated virus (AAV) and retrovirus vectors are suitable for use in the methods and compositions of the present disclosure.The construction of such vectors is known to those skilled in the art (see, for example, U.S. Pat. Nos. 4,797,368, 5,691,176, 5,693,531, 5,880,102, 6,210,393, 6,268,213, 6,303,362 and 7,045,344).Non-viral methods can also be used for gene delivery, including, but not limited to, gene gun application of plasmids (e.g., non-viral expression vectors encoding precursors of one or more carboxyl anhydrases described herein).Another non-viral method of gene delivery is electroporation. Alternative transplantable cell lines can be engineered to produce the desired peptide (or library).
[0081] In various embodiments, the viral vector is an AAV vector. AAV is a DNA virus that is not known to cause human disease, which makes it a desirable gene therapy option. The AAV genome is composed of two genes, rep and cap, flanked by inverted terminal repeats (ITRs) that contain recognition signals for DNA replication and viral packaging. AAV requires co-infection with a helper virus (i.e., adenovirus or herpes virus) or expression of a helper gene for efficient replication. AAV vectors used for administration of therapeutic nucleic acids typically have most of the parent genome deleted, so that only the ITRs remain, although this is not essential. Upon delivery of the AAV rep protein, AAV vectors containing AAV ITRs can be integrated into specific regions of the genome, if desired. Host cells containing the integrated AAV genome do not show changes in cell growth or morphology. Thus, long-term expression of therapeutic factors from AAV vectors can be useful for treating persistent and chronic diseases. AAV vectors are optionally based on AAV type 1, AAV type 2, AAV type 3 (including type 3A and type 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, or AAV type 11. The genomic sequence of AAV, as well as the sequences of the ITRs, Rep proteins, and capsid subunits, are known in the art. See, e.g., International Patent Publication Nos. WO 00 / 28061, WO 99 / 61601, WO 98 / 11244, as well as U.S. Pat. No. 6,156,303, Srivistava et al. (1983) J Virol. 45:555, Chiorini et al. (1998) J Virol. 71:6823, Xiao et al. (1999) J Virol. 73:3994, Shade et al. (1986) J Virol. 58:921, and Gao et al. (2002) Proc. Nat. Acad. Sci. USA 99:11854.
[0082] An expression vector typically contains various nucleic acid sequences necessary for the transcription and translation of an operably linked coding sequence. For example, an expression vector may contain an origin of replication, a polyadenylation signal, an internal ribosome entry site (IRES), a promoter, an enhancer, and the like. The vector of the present disclosure preferably contains a promoter operably linked to a CA10 (or Car10) or CA11 (or Car11) coding sequence. In various embodiments, the vector of the present disclosure preferably contains a promoter operably linked to a CA8 (or Car8) or CA8 fragment (or Car8 fragment) coding sequence. "Operably linked" means that a control sequence such as a promoter is in the correct position and orientation relative to another nucleic acid sequence to exert its effect (e.g., initiation of transcription) on the nucleic acid sequence. The promoter may be native or non-native to the nucleic acid sequence to which it is operably linked, may be native or non-native to a particular target cell type, and in various embodiments, the promoter may be a constitutive promoter, a tissue-specific promoter, or an inducible promoter (e.g., a system of promoters including Tet on / off elements, RU486 inducible promoters, ecdysone inducible promoters, rapamycin inducible promoters, or metallothionein promoters). For example, in various embodiments, a system of inducible promoters is employed that allows the use of small molecules to induce or stop the production of analgesic peptide production. Examples of promoters include, but are not limited to, sensory neuron specific promoters (such as Nav1.8 promoter), somatosensory specific promoters (such as advillin promoter), p175 promoter, or TrkA (nerve growth factor receptor) promoter. Other promoters include, but are not limited to, TrkB, TrkC, Nav1.7, CGRP, ASIC3, NPY, NK1, 5HT, GRIN3A, or NF200 promoters. Non-limiting examples of various promoter sequences are provided herein as Figures 21A-30.
[0083] Optionally, the viral coat or capsid (i.e., particle surface) is modified to adjust the tropism of the virus. For example, the genome of one serotype of a virus can be packaged within a capsid of a virus of a different serotype, for example, to avoid an immune response. Alternatively (or in addition), components of the capsid can be modified, for example, to expand the cell types transduced by the resulting vector, to avoid (in whole or in part) transduction of undesirable cell types, or to improve transduction efficiency of a desired cell type. For example, transduction efficiency is generally determined by reference to a control (i.e., an unmodified matched viral vector). Improved transduction efficiency can result in, for example, at least about 25%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 100% improvement in the transduction rate of a given cell type. If desired, the capsid can be modified so that it does not efficiently transduce non-target tissues such as hepatocytes or germ cells (e.g., levels of transduction of the desired target tissue(s) of 50% or less, 30% or less, 20% or less, 10% or less, 5% or less).
[0084] pain "Pain" is generally described in terms of duration, cause, and / or affected area of the body. The present invention includes treatment of all types of pain, including neuropathic pain (e.g., pain initiated or developed by a lesion or disease of the somatosensory nervous system), inflammatory pain (e.g., pain developed by activation and / or sensitization of nociceptive pain pathways by inflammatory mediators), and / or nociceptive pain (e.g., pain developed by tissue injury or damage). Many pain disorders or pain events cannot be easily classified and may involve aspects or characteristics that overlap with these general classes. Pain is also classified with respect to location within the body, with somatic pain resulting from activation of pain receptors on the body surface or in musculoskeletal tissues, whereas visceral pain is felt in the viscera and is usually developed by activation of pain receptors in the thorax, pelvis, or abdomen.
[0085] Neuropathic pain occurs when there is actual nerve damage. Primary afferent somatosensory nerves represent the peripheral sensory nerves and communicate with second order neurons in the dorsal horn of the spinal cord. Secondary somatosensory nerves connect the spinal cord to the brainstem and tertiary neurons. Trauma (e.g., injury, surgery, toxic exposure, cancer, and / or metabolic or infectious disease) can all damage somatosensory pathways and cause spontaneous pain. Neuropathic pain can manifest as a burning, tingling, electric shock, or stabbing sensation, or can be associated with more severe sensations including pricking, piercing, cutting, or drilling. This type of pain usually occurs in waves of frequency and intensity and is usually diffused to one or all of the body. Examples of neuropathic pain conditions include, but are not limited to, spinal cord injury-mediated pain, central pain syndromes (e.g., caused by lesions in the nervous system), pain associated with peripheral nerve injury due to locked-in syndrome (e.g., carpal tunnel syndrome, cubital tunnel syndrome, or tarsal tunnel syndrome), multiple sclerosis, fibromyalgia, shingles, viral-associated neuropathy, painful traumatic mononeuropathy, polyneuropathy, diabetic neuropathy, postoperative pain syndromes (e.g., postmastectomy syndrome, postthoracotomy syndrome, phantom pain), and complex regional pain syndromes (e.g., reflex sympathetic dystrophy and causative pain).There are many causes of neuropathic pain, including, for example, exposure to chemicals (e.g., chemotherapy), trauma (e.g., amputation, herniated disc, or spinal cord injury), exposure to radiation, metabolic disease, infection, and cancer.
[0086] Nociceptive pain is caused by injury to body tissues and is usually described as a sharp, aching, or throbbing pain. This type of pain may be from benign pathological properties or from tumors or cancer cells that grow and crowd other body parts near the cancer site. Nociceptive pain may also be caused by cancer spreading to bones, muscles, or joints, or by organ or blood vessel blockage. Nociceptive pain may be associated with inflammation, including, for example, arthritic pain (such as rheumatoid arthritis or osteoarthritis) and inflammation-induced visceral pain (such as pain associated with inflammatory bowel disease, irritable bowel syndrome IBS, etc.). Examples of nociceptive pain include, for example, sprains, fractures, burns, bumps, bruises, pain from inflammation (e.g., inflammation caused by infection, trauma, or joint disorders) or blockage, and myofascial pain (which may indicate abnormal stress on muscles or tendons). Cancer pain may be nociceptive or neuropathic.
[0087] In various aspects, the method includes, for example, the treatment of long-term persistent pain, chronic pain, breakthrough pain, subacute pain, acute pain, and cancer pain. Acute pain is generally a limited physiological response to a discrete bodily injury (e.g., inflammation, surgery, fracture, headache, sprain, contusion, burn, or exposure to chemicals). Acute pain generally lasts for 3-6 months. Chronic pain lasts longer than would be expected for healing from a discrete bodily injury, for example, more than 3 months. Chronic pain is associated with injuries such as back pain, trauma (e.g., surgery or wound) resulting in nerve injury (including spinal cord injury), myofascial pain, arthritis, cancer-related pain, neuropathic pain, and fibromyalgia. In some embodiments, pain encompasses acute pain superimposed on chronic pain, where the rapid onset of acute pain superimposes on persistent chronic pain.
[0088] The efficacy of treating or preventing pain in a subject who needs to treat (i.e., reduce, alleviate, suppress or alleviate) or prevent pain can be determined using any suitable method. In animal models, analgesic efficacy can be measured using, for example, tail withdrawal test, tail flick test, bee venom test, capsaicin test, or tail clip test. Animal pain models are well characterized in the art and described, for example, in Lariviere et al., Pain 97 (2002) 75-86. In humans, the efficacy (or necessity) of treatment can be monitored or determined using, for example, pain scores, time to remedying, and quality of life measurements. Several tools are used in clinical settings to establish numerical assessment of pain intensity (see, for example, McCaffery et al., (1989), Pain: Clinical manual for nursing practice, Mosby St. Louis, MO) or verbal rating scales that classify pain as mild, moderate, or severe. Reduction in the subject's assessment of pain (intensity, frequency), ability to resume activity, increased ability to sleep, and reduced need for pain medication are indicators of analgesia.
[0089] The present disclosure provides a method for treating pain in a subject in need of such treatment. It is not necessary to eliminate 100% of the pain of the subject in order to "treat" pain. Any reduction in pain sensation or symptoms constitutes a beneficial biological effect in the subject. In various embodiments, the method reduces the severity (which may include reducing the need for and / or amount (e.g., exposure) of other drugs and / or therapies commonly used in these conditions), duration, and / or frequency of pain. To "prevent" pain, it is not necessary to completely eliminate pain sensation, and any attenuation or delay of the onset of pain or related symptoms is contemplated. In this regard, optionally, the expression vector is administered to the subject as a prophylactic before the onset of pain.
[0090] Various embodiments of the present disclosure allow for the targeting of pain-transmitting somatosensory nerves (e.g., Nav1.7; Nav1.8; Nav1.9; Trk-A; 5HT, etc.) to safely produce analgesia. In some aspects, the method minimizes or avoids undesirable off-target effects, such as the indiscriminate loss of desirable somatosensory and / or motor functions associated with other parenteral (anti-NGF) or ion channel inhibitors. Optionally, the expression vector can be contained within a viral capsid (e.g., viral particle) to allow for long-term expression of CA10 and CA11 (or CA8), minimizing the need for repeated invasive interventions currently required for long-term management.
[0091] The disclosure further provides use of an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase 10 or carbonic anhydrase 11 (or carbonic anhydrase 8) in treating or preventing pain in a subject in need of such treatment or prevention, use of an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase 10 or carbonic anhydrase 11 (or carbonic anhydrase 8) in the preparation of a medicament for treating or preventing pain in a subject in need of such treatment or prevention, and an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase 10 or carbonic anhydrase 11 (or carbonic anhydrase 8) for use in treating or preventing pain in a subject in need of such treatment or prevention.
[0092] Pain Relief Screening The present disclosure further provides a stock comprising multiple gene transfer vectors encoding one or more analgesic candidate peptides. The stock can have any desired titer of vector, typically measured in plaque forming units (pfu) in the context of viral vectors. Typically, the stock contains approximately 10 5 pfu / ml ~ approx. 10 8pfu / ml. In some embodiments, the stock is homogenous. In some embodiments, the DNA sequence encoding the candidate analgesic peptide(s) (or precursors) differs between vectors in the stock. In various embodiments, each DNA sequence encoding the candidate analgesic peptide(s) (or precursors) between vectors in the stock defines a random or semi-random peptide library. Optionally, the DNA sequence encodes a precursor of a carboxyl anhydrase peptide.
[0093] The present disclosure provides a method for detecting peptides with desired analgesic properties. A population of expression vectors described herein is introduced into a population of host cells (e.g., as NBL cells or HEK293 cells) under conditions suitable for expression of the encoded peptides. One or more host cells are then assayed for a desired effect that represents the desired analgesic properties. Optionally, the host cell(s) are assayed against a positive and / or negative control drug, such as those described herein for Car8 / CA8. The control drug can be a drug known to reduce the desired effect (positive control) or a drug known not to exhibit the desired effect (negative control). Optionally, the method further includes deducing a DNA sequence that encodes a peptide that demonstrates the desired analgesic properties.
[0094] The host cell(s) can be in vivo or in vitro. For in vitro applications, the assay is optionally performed in a multi-well plate (e.g., 96-well plate) that can facilitate high-throughput screening for the desired pharmacodynamic and / or analgesic effects. In such applications, the expression vectors from the library are optionally introduced into the wells at a calculated titer of less than one vector per well (usually about 0.5 vectors per well) to minimize the statistical probability that multiple vectors will transfect or infect the cells. In some embodiments, the expression vector is a viral vector, and in other embodiments, the expression vector is a plasmid or phage. However, if the plasmid or phage (e.g., BAC) contains the viral genome, the cells in the well will produce viral particles. Alternatively, a BAC system containing the viral genome (including the respective DNA sequence and promoter) can be used to transform a larger number of cells and rescue the viral particles. The resulting viral particles can then be used for the assay. For example, when about 10,000 BACs containing a HSV backbone carrying a random or semi-random library are introduced into a 6-well dish of host cells, about 100,000 virus particles can be collected after about 24 hours. These can be employed in the assay. Desirably, about 30,000 virus particles (about three times the original number of vectors) should be used to increase the likelihood that all members of the library are in the assay. The desired effect to be assayed can be any suitably measurable effect, such as apoptosis, antagonism of ITPR1 activation and calcium release, or other aspects of this cell signaling pathway. Exemplary assays and methodologies are provided in the examples, which should not be construed as limiting.
[0095] In some embodiments, the host cell is in vivo (i.e., an animal model), which is particularly suitable when the desired effect to be assayed is behavioral in nature. For example, the analgesic effect may include, for example, a reduction in hyperalgesia or allodynia caused by an external stimulus or a medical condition. In such an embodiment, the library is clonally expanded into multiple random stocks of vectors, each of which is substantially homologous, and each stock may be introduced into an animal model of pain. The vector DNA from the stock that reduces the pain response of the animal may then be sequenced to identify the encoded analgesic peptide.
[0096] Formulations and Dosage Regimen In various embodiments, the expression vector is provided in a composition (e.g., a pharmaceutical composition) that includes a physiologically acceptable (i.e., pharmacologically acceptable) carrier, buffer, excipient, or diluent. Any suitable physiologically acceptable (e.g., pharma- ceutical acceptable) carrier can be used within the context of the present disclosure, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition is administered and the particular method used to administer the composition. The composition can also include an agent that promotes the uptake of the expression vector into host cells. Suitable composition formulations include aqueous and non-aqueous solutions, isotonic sterile solutions that may contain antioxidants, buffers, bacteriostatic agents, and solutes that make the formulation isotonic with blood, and aqueous and non-aqueous sterile suspensions that may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives. The composition can be provided in unit-dose or multi-dose sealed containers such as ampoules and vials, and can be stored in a lyophilized (freeze-dried) state, requiring only the addition of sterile liquid carrier such as water immediately before use.The composition comprising the expression vector encoding CA8, CA8 fragment, CA10 or CA11 is in one embodiment placed in a container with packaging material that provides instructions on the use of the composition.In general, such instructions include specific wording that describes the concentration of reagents, and in certain embodiments, the relative amounts of excipient components or diluents (e.g., water, saline, or PBS) that may be required to reconstitute the composition.
[0097] In various embodiments, the expression vector is incorporated into lipid vesicles (optionally enhancing uptake) or provided in the form of nanoparticles (e.g., by incorporation with proteins, lipids, carbohydrates, or combinations thereof). Physical bombardment can be used to increase the uptake of the vector by cells. Optionally, the expression vector is provided with a chemical-based transduction enhancer. Examples of transduction enhancers include polyplex technology, in which positively charged DNA is combined with anionic and neutral lipids to construct polyplexes to enhance uptake. Polyplexes represent another form of chemical delivery complex for expression units. Generally, polyplexes are composed of cationic polymers, and the creation is based on ionic interactions and self-assembly. Another example, cationic liposomes, interact with cell membranes to enhance uptake via endocytosis. To improve transfection efficiency, neutral lipids such as DOPE are added to enhance release into the cytoplasm and avoid lysosomal degradation. In another embodiment, polymersomes are used as an alternative to liposomes. Polymersomes are synthetic versions of liposomes (vesicles with a lipid bilayer) that tend to be more stable, mechanically stronger, and have a longer shelf life than liposomes. Endosomolytic agents include inactivated adenoviruses that facilitate the escape of nanoparticles from endocytic vesicles created during uptake.
[0098] Polycationic nanoparticles are an advantageous embodiment due to their low toxicity, high carrying capacity and ease of preparation.Polyethyleneimine and chitosan are suitable polymeric carriers for the delivery of expression vectors.Other polycationic carriers include poly(beta-amino esters) and polyphosphoramidates.Dendrimers are spherical, highly branched polymers that are useful in supporting the cell targeting of expression units.
[0099] One embodiment involves the use of cationic dendrimers. These molecules naturally attract negatively charged genetic material such as DNA or RNA, and the complex is taken up into the target cell via endocytosis. In recent years, dendrimers have been produced using kinetic-driven chemistry that reduces speed and processing time. "Pliostar" dendrimers can carry a variety of expression units, including DNA or RNA, and efficiently transfect target cells with high efficiency and little or no toxicity.
[0100] Inorganic nanoparticles such as gold, silica, iron oxide, calcium phosphate, etc., represent another chemical means of delivering nucleic acids to target cells. Advantages of inorganic nanoparticles include stable long-term storage, low-cost manufacturing, minimal immunogenicity, and resistance to microbial attack. Nano-sized inorganic particles (e.g., less than 500 nm, preferably less than 250 nm, most preferably less than 100 nm) represent another option to enhance transduction, if desired. Nanoparticles efficiently trap DNA or RNA, allowing escape from endosomes without degradation.
[0101] Cell-penetrating peptides, also called peptide transduction domains (PTDs), are short peptides (<40 amino acids) that efficiently cross cell membranes while covalently or non-covalently binding to various expression units to facilitate cell entry. PTDs can be constructed to deliver exogenous nucleic acids to specific organelles by incorporating localization peptide sequences.
[0102] Some well-known physical methods of delivering expression units to target cells include electroporation, sonoporation (ultrasonic frequencies that cavitate the membrane to better access the expression units), magnetofection (the expression units are complexed with magnetic particles that enhance access to the target cells using magnets), and the use of hydrodynamic methods.
[0103] In various embodiments, the expression vector is incorporated into a viral capsid (viral particle) that represents an infectious viral particle (capsid, containing single- or double-stranded DNA, RNA, or other nucleic acid capable of encoding the required peptide(s)), which is advantageous for supporting latent infection and stable long-term analgesic peptide production. Peptide expression is intracellular and can affect neuronal excitability and function in a manner that produces analgesia or antihyperalgesia.
[0104] The expression vector (e.g., viral particle) is administered in an amount and at a location sufficient to provide some improvement or benefit to the subject, i.e., to reduce or suppress the subject's sensation or perception of pain. Depending on the situation, the composition comprising the expression vector is applied or instilled into a body cavity, applied directly to a target tissue, and / or introduced into the circulatory system. For example, in various situations, it may be desirable to deliver the composition comprising the expression vector by intravenous, intraperitoneal, intraoral, intraluminal (e.g., bladder, gallbladder, bile duct, pancreatic duct, or paranasal sinus), intramuscular, intraocular, transcorneal, intraarterial, intraportal, intralesional, intradermal, intraarticular, intraneuronal, intraganglionic, periganglionic, intradermal, transdermal, subcutaneous, intraperitoneal, intranasal, inhalation (e.g., upper and / or lower respiratory tract), enteral, vaginal, or rectal means. In various embodiments, the expression vector is administered directly to the pancreatic duct, which is useful, for example, for treating pain associated with pancreatic cancer or pancreatitis). In various aspects, the expression vector is administered to the trigeminal ganglion. If desired, the expression vector is administered locally via intra-arterial or intravenous administration supplying the region of interest. In various aspects, the expression vector described herein is administered directly or indirectly to peripheral somatosensory nerves. In one embodiment, the route of administration includes direct administration (e.g., injection or infusion) to the dorsal root ganglion, other ganglia or somatosensory neurons, or the spinal cord. Optionally, the expression vector is administered via intra-articular injection or peripheral (e.g., sciatic) nerve injection. In various aspects, the expression vector is administered by intra-articular insertion, for example, to treat chronic nociceptive pain by sedating the somatosensory nerves supplying the affected arthritic joint. In other embodiments, the expression vector is administered to various cavities, ducts, sinuses, or organs via a microcatheter or with direct visualization using an endoscope. Other embodiments include the use of needles to facilitate localization of the expression vector to the area of pain. For example, the present disclosure contemplates administration of the expression vector to the site where pain occurs (e.g., an organ or other body site such as a joint) using a catheter or needle. Still other embodiments include the use of image analysis to guide deposition of the expression vector using, for example, fluoroscopy, ultrasound, CT or MRI.Further embodiments include the use of formulations that facilitate delivery of expression vectors to the intestine via the intradermal route by avoiding degradation of the stomach or upper gastrointestinal tract.
[0105] In various embodiments, enteric coating encapsulation can be used to prevent degradation and inactivation of the expression vector by gastric acid. The formulation may include the incorporation of a capsule composed of enteric coated granules developed using Eudragit L30D-55 as the enteric polymer that encases the expression vector. Optimization of the capsule formulation can be achieved with an optimal protective coating using Eudragit L30D-55 demonstrating the highest number of live vectors after 2 hours incubation in acidic medium and 1 hour disintegration time in pH 6.8 buffer. The amount of protection of Eudragit L30D-55 in the capsule correlates with gastric juice resistance. Protective properties against artificial gastric juice are observed when capsules are prepared from granules composed of vector, corn starch, lactose monohydrate, polyvinylpyrrolidone and coated with 12.5% (m / V) Eudragit L30D-55. Other coatings can be used to provide the enteric protective properties of the commercially available polymer EUDRAGIT® L100-55 on gelatin capsules and also on DRcaps®. Still other enteric coatings include, for example, Vcaps® (Lonza) enteric coated capsules, which incorporate polymer formulations that allow for effective delayed release, gastric protection, and protection of compounds with mild to moderate acid sensitivity, and enTRinsic Drug Delivery Technology, which incorporates polymer formulations that provide enteric protection to small and large molecules that are very acid sensitive.
[0106] Yet another embodiment providing gastroresistance to labile vectors can be obtained by adding enteric polymer systems to other dosage forms: tablets, minitablets, pellets and granules (usually filled into a capsule shell) are the most common enteric dosage forms utilizing the polymers mentioned elsewhere.
[0107] In various aspects, the expression vector is injected into a peripheral nerve (e.g., sciatic, femoral, suborbital, trigeminal, facial, or suprascapular) or via intraganglionic injection. In other embodiments, the expression unit can be a naked single-stranded or double-stranded DNA expression unit that is circular and resistant to nuclease destruction. In other embodiments, the vector can be incorporated into lipid vesicles for better absorption. Still other embodiments include single-stranded or double-stranded DNA expression units incorporated into proteins, lipids, carbohydrate molecules, or combinations thereof as nanoparticles. Still other embodiments include physical methods of entry into target cells. Exemplary embodiments include the use of chemical methods to enhance uptake of expression vector entry into target cells. Other embodiments utilize a combination of physical, chemical, and biological methods for enhanced uptake of expression vector into target cells.
[0108] Alternatively, the composition is administered locally via implantation of a membrane, sponge, or another suitable material into which the composition has been absorbed or encapsulated. When an implantation device is used, in one embodiment, the device is implanted into a suitable tissue and delivery of the expression vector is via, for example, diffusion, sustained release bolus, or continuous administration.
[0109] The particular dosing regimen for a particular subject will depend in part on the amount of therapeutic agent administered, the route of administration, and the cause and extent of any side effects. The amount administered to a subject (e.g., a mammal, such as a human) in accordance with the present disclosure should be sufficient to affect the desired response over a reasonable time frame. In various embodiments of the method of treating or preventing pain in a subject, CA8 (or Car8), CA8 (or Car8) fragments (CA8-204, CA8-204 C , CA8-204 GThe expression vector encoding CA10 (or Car10), CA11 (or Car11), CA8-202 and CA8-203, CA10 (or Car10), or CA11 (or Car11) is administered in an amount that induces analgesia. In other words, the dose of the composition administered is sufficient to reduce, alleviate, inhibit, or relieve pain. 4 ~10 15 10 units of installation (e.g. 10 7 ~10 12 transducing units), or at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 , or 10 15 , or a larger number of introduction units (e.g., about 10 10 or 10 12 At least about 10 units of installation 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 or 10 14 Exemplary doses of viral particles with a genome equivalent titer of 10 transduction units. In some conditions, long-term treatment is required, which may or may not involve multiple administrations over time. Equivalent doses of vector in genome equivalents, which can be quantified in vitro using quantitative PCR (qPCR) in terms of expression units, are in the range of 10 4 ~10 15 (An expression unit is an individual genetic unit capable of producing one peptide as described herein.) In various embodiments, the dose is 10 7 ~10 12 Expression units, or at least about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 1011 , 10 12 , 10 13 , 10 14 or 10 15 Expression units or more (e.g., about 10 10 or 10 12 etc., at least about 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 expression units).
[0110] CA8, CA8 fragment (CA8-204, CA8-204 C , CA8-204 G Expression vectors containing nucleic acids encoding CA10, CA11, CA202, and CA203, CA12, CA13, CA14, CA15, CA16, CA17, CA18, CA19, CA20, and CA21., including CA8-202 and CA8-203), CA10, or CA11 (or their murine versions) are administered in combination with other substances (e.g., therapeutic agents) and / or other treatment modalities to achieve additive (or augmented) biological effects. This embodiment includes simultaneous (i.e., substantially simultaneous) and non-simultaneous administration (i.e., administration at different times in any order, whether overlapping or not) of the expression vector and one or more additional suitable agent(s). It will be understood that in certain embodiments, the different components are administered in the same or separate compositions, and by the same or different routes of administration.
[0111] According to a further aspect of the disclosure, there is provided a use or method according to any other aspect of the invention, in which CA8, CA8 fragment (CA8-204, CA8-204 C , CA8-204 G, including CA8-202 and CA8-203), CA10 or CA11 vectors are administered separately, sequentially, or simultaneously in combination with one or more agents useful for pain management. Examples of additional agents include, but are not limited to, opioid analgesics (e.g., morphine, hydromorphone, oxymorphone, fentanyl, codeine, dihydrocodeine, oxycodone, or hydrocodone), nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, diclofenac, ibuprofen, naproxen, oxaprozin, or cyclooxygenase 2 (COX-2) inhibitors), sedatives (e.g., barbiturates), muscle relaxants, antidepressants, antiepileptics (e.g., carbamazepine, or valproic acid), additional anesthetics, and corticosteroids (e.g., dexamethasone).
[0112] The invention thus generally described will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the invention. EXAMPLES
[0113] Example 1 This example demonstrates that carbonic anhydrase 8 (CA8 human gene symbol, Car8 rodent orthologue), carbonic anhydrase 10 (CA10 human gene symbol, Car10 rodent orthologue) and carbonic anhydrase 11 (CA11 human gene symbol, Car11 rodent orthologue) regulate the ITPR1 cytosolic free calcium signaling pathway. ITPR is thought to transmit signals resulting from inositol 1,4,5-triphosphate (IP3) signaling molecules from ITPR, which play an important role in inflammatory pain behavior, and metabotropic receptor activation that generates intracellular calcium release. Zhuang et al.,PLoS One,2015. The data described herein for the first time show that CA8 / Car8), CA8 / Car8 fragments (including CA8-204), CA10 / Car10, and CA11 / Car11 function to inhibit IP3 activation of ITPR1 calcium release channel, intracellular calcium release, and surprisingly inhibit analgesic response to therapeutic analgesics (e.g., morphine and clonidine) by inhibiting intracellular calcium release, and furthermore, these CA peptides produce significant analgesia in models and treat or prevent chronic neuropathic pain. Also surprisingly, CA8 / Car8 fragments (including CA8-204) and CA10 / Car10 do not bind to ITPR1 (demonstrated by co-immunoprecipitation), but in sharp contrast to CA8 (Car8) peptide, intracellular overexpression of CA8 / Car8 fragments (including CA8-204) and CA10 / Car10 peptide inhibits ITPR1 activation (phosphorylation) in response to forskolin- and ATP-stimulated intracellular calcium release.
[0114] Furthermore, the data provided herein demonstrate for the first time that overexpression of CA8 selectively inhibits nerve growth factor (NGF) signaling almost exclusively in NBL cells via ITPR1, as indicated by nearly complete 2-APB. CA8 also inhibits NGF-induced ITPR1 activation (pITPR1), intracellular calcium release. Surprisingly, overexpression of CA8 (Car8) DRG has also been demonstrated to prevent and treat chronic neuropathic pain after spinal nerve (SNL) root injury. The following examples establish that introduction of DRG CA8 (Car8) and CA10 (Car10) and overexpression of CA8 (Car8) and CA10 (Car10) proteins downregulates ITPR1 activation (e.g., pITPR1 at Ser-1755) and inhibits intracellular calcium release. Surprisingly, despite the lack of amino acid homology between CA8 and CA10 (Car10) proteins, CA8 and CA10 (Car10) proteins also produce remarkable analgesia after sciatic nerve injection that prevents mechanical allodynia and thermal hyperalgesia in chronic inflammatory and neuropathic pain models (spinal nerve ligation (SNL)).
[0115] Morphine produces analgesia by eliciting the release of intracellular calcium. Data provided herein demonstrate that CA overexpression inhibits morphine-induced ITPR1-mediated calcium release in NBL cells. Specifically, these data show that DRG Car levels are associated with half-maximal analgesic responses to morphine and clonidine. Higher Car expression is associated with higher half-maximal analgesic doses of morphine and clonidine (Levitt et al., 2017). These data suggest for the first time that CA may induce analgesic tolerance that shifts the dose response to clonidine and morphine to the right (e.g., a larger dose of analgesic is required to produce the same amount of analgesic response), and these effects are associated with the inhibition of intracellular calcium release. This is unexpected considering that morphine requires intracellular calcium release to produce an analgesic response. It is therefore surprising that instead of producing nociceptive pain by inhibiting calcium-regulatory pathways required for opioid and clonidine analgesic responses, CA produces marked analgesia.
[0116] material and method Animals: All experiments and procedures were performed according to current guidelines for investigators of experimental pain in conscious animals and were approved by the University of Miami Animal Care and Use Committee. Adult male C57BL / 6 mice weighing 20-35 grams were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in a home cage environment with food and water available ad libitum. Animals were housed in a humidity- and temperature-controlled virus / antigen-free facility on a 12-h light / dark cycle. Animals were allowed to acclimate for 7 days prior to surgery and to become accustomed to the experimental apparatus prior to testing.
[0117] Generation of viral constructs: As an example, we will describe how to generate adeno-associated vectors expressing mouse or human V5-Car10 or V5-CA10 proteins. Car10 (mouse) and CA10 (human) cDNAs were purchased from ATCC. Their gene products were amplified by Eppendorf Recycler gradients (Model 5331) and cloned between the BamHI and XhoI (NEB) restriction sites of pcDNA3.1 / V5-HisA (Invitrogen™ Life Technologies, Carlsbad, CA) using forward primer: TTTGGATCCGCCACCATGGCT-GACCTGAGCTTCATTG and reverse primer: TTTCTCGAGCTGAAAGGCCGCTCGGA-TG. Next, the V5-Car10 or V5-CA10 construct was amplified from pcDNA3.1 / V5-HisA and cloned between the BamHI and BglII restriction sites of the pAAV-MCS vector, one component of the AAV Helper-Free System (Agilent Technologies, Santa Clara, CA), using the forward primer: CTCGGATCCGCCACCATGGC and the reverse primer: CTCGGATCCGCCA-CCATGGC.
[0118] Recombinant AAV8-V5-Car10 and AAV8-V5-CA10 viral particles were produced. Briefly, vector plasmids and packaging plasmids AAV8 733(5) and pHelper (Agilent Technologies, Santa Clara, CA) were co-transfected into HEK293 cells at 70% confluence using calcium phosphate precipitation method. Cells were incubated at 37°C and 5% CO2 for 48 hours. After 48 hours, cells were harvested and freeze-thawed three times to release AAV particles from cells. After 30 minutes of Benzonase® Nuclease (Sigma) treatment, crude lysates were clarified by low-speed centrifugation. The supernatant was loaded onto a discontinuous iodixanol step gradient in an OptiSeal™ tube (Beckman Coulter) and centrifuged at 69,000 rpm (350,000 g) for 1 h at 18 °C in a Type 70Ti rotor (Beckman Coulter). Fractions containing AAV particles were collected and further purified by column chromatography on a 5 ml HiTrap column (GE Healthcare) using an AKTA FPLC system (GE Healthcare). Approximately 25 mL was eluted from the column using elution buffer (20 mM Tris, 215 mM NaCl, pH 8.0), and the AAV particles were concentrated and buffer exchanged into 200 μl in HBSS (Invitrogen) using an Amicon Ultra-15 50K concentrator (Millipore). The purified AAV particles were then titrated for genome content (expression units) using qPCR methods. 1–3 × 10 per mL 14 Titers ranging from 100 GC (genome copies) were obtained.
[0119] Cell culture and transfection: Human neuronal (e.g., NBL), human non-neuronal (e.g., HEK293) cells, or dispersed rodent primary DRG cells can be used. HEK293 cells (catalog no. CRL-1573 ATCC Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (DMEM-Glutamax catalog no. 0566, Invitrogen) supplemented with 10% fetal bovine serum FBS (catalog no. 16140 ThermoFisher Scientific, Waltham, MA) and 1% penicillin / streptomycin (catalog no. 15140 ThermoFisher Scientific, Waltham, MA). Cells were plated at 1.0 × 10 per well in a 6-well plate. 5 Cells were seeded at a density of 1000 μg / ml. The next day, cells were transfected with plasmids via Lipofectamine LTX Reagent and Plus (Cat. No. 15338 ThermoFisher Scientific, Waltham, MA). For each transfection, 2 μg of AAV2-ITR (control), AAV2-V5-Car10, or AAV2-V5-CA10 vector was used. In various embodiments of the present disclosure described herein, 2 μg of expression vector (including positive and negative controls) was used in situations where AAV2 was not the viral vector employed.
[0120] Sciatic nerve injection of expression vectors (adeno-associated AAV8-V5-Car10 and AAV8-V5-CA10 vectors): Mice were anesthetized by intraperitoneal injection of ketamine, xylazine and acepromazine cocktail (VEDCO, Saint Joseph, MO). After sciatic nerve exposure, approximately 1.5 μl of AAV8-free viral particles (1.36E 13 viral particles, SL100832 SignaGen Laboratories Rockville, MD), AAV8-V5-Car10 and AAV8-V5-CA10 (1.06E each, 14 1.66E virus particles 141000 virions) were injected into the sciatic nerve using a 35-gauge Nanofil needle (World Precision Instruments, Sarasota, Fla.) The sciatic injection site was approximately 45 mm from the tip of the third digit.
[0121] Inflammatory hyperalgesia model: Mice received an intradermal injection of 30 μl of 1% carrageenan (Cat. No. 22049 Sigma, St Louis, MO) 2.5 mg / ml in sterile 0.9% saline or Complete Freund's Adjuvant (CFA) (Cat. No. F5881 Sigma, St Louis, MO) 0.5 mg / ml in sterile 0.9% saline into the left hind paw. Fehrenbacher et al., Curr Protoc Pharmacol. 2012; Chapter 5: Unit 54.
[0122] Neuropathic pain model: First, mice were anesthetized by intraperitoneal injection of ketamine, xylazine hydrochloride and acepromazine (VEDCO, Saint Joseph, MO) for induction of peripheral neuropathy. Then, tight ligation of the spinal nerve (left L5 in mouse model) was performed using a procedure previously described. Kim et al., Pain. 1992;50(3):355-363.
[0123] Behavioral testing: Thermal and mechanical sensitivity were measured by the Hargreaves test and von Frey filament threshold calculation, respectively. See, for example, Boyce-Rustay et al. Methods Mol Biol. 2010; 617: 41-55, Hargreaves et al., Pain. 1988; 32 (1): 77-88, and Chaplan et al., J Neurosci Methods. 1994; 53 (1): 55-63. Testing was performed in a quiet room with daylight-like lighting. Animals were habituated to the behavioral room and apparatus for at least 60 minutes for one week before data were collected by a blinded investigator. Thermal sensitivity testing was performed using an IITC Plantar Analgesia Meter apparatus (IITC Life sciences, Woodland Hills, CA) with a plastic box placed on a glass plate at a constant temperature (30°C). The plantar surface of the mouse paw was exposed to a beam of radiant heat to induce paw withdrawal. To prevent potential injury, baseline latencies were adjusted to 5–9 s, with a maximum cutoff of 20 s. The latency in seconds from the onset of the high-intensity light beam to paw withdrawal was defined as paw withdrawal latency. Two consecutive trials were averaged to establish paw withdrawal latency. Mechanical sensitivity testing was performed in an inverted plastic box placed on an elevated mesh platform. The mouse hind paw was pressed for 1–2 s with one of a series of von Frey filaments (Stoelting Co, Wood Dale, IL) with logarithmically increasing stiffness, presented perpendicular to the plantar surface of each hind paw, and the up-down method was used to determine the 50% threshold.
[0124] Pharmacodynamics (calcium release bioassay): 15 mm glass coverslips (catalog number 72228 Electron Microscopy Sciences, Hatfield, PA) were coated with poly-D-lysine (Sigma) and then laminin and 1×105 cells were seeded on each glass coverslip. After 24 hours, cells were transfected with AAV2-ITR, AAV2-V5-Car10, or AAV2-V5-CA10 vectors as described above. In embodiments where AAV2 is not employed, other expression vectors (including viral vectors) are used. Fura-2AM (catalog number F1221 ThermoFisher Scientific, Waltham, MA) was dissolved as a stock solution in DMSO (50 μg in 50 μl) and 1% pluronic acid-127 (catalog number P2443 Sigma, St Louis, MO). 48 hours after seeding, cells were loaded with 2 μM Fura-2AM dye for 45 min at room temperature in the dark in standard Ca+2 buffer containing 125 mM NaCl, 2 mM MgCl, 4.5 mM KCl, 10 mM glucose, 20 mM HEPES, 2 mM CaCl2, pH 7.4.25. After dye loading, coverslips were removed from the Ca +2 For image analysis and ATP stimulation experiments, the coverslips were placed in a recording chamber on a Leica DMI6000B microscope (catalog no. QR-42LP Warner Instruments Hamden, CT) and incubated with CaCl containing 125 mM NaCl, 4 mM MgCl, 4.5 mM KCl, 10 mM glucose, 20 mM HEPES, pH 7.4. +2The cells were perfused with free buffer at room temperature (approximately 22°C). For ratiometric image analysis of Fura-2AM, excitation light was filtered with an ultrafast wavelength switcher to provide wavelengths of 340 nm and 384 nm and captured with a high-speed digital camera (Leica DFC365FX). Activation of the ITPR1 channel was achieved via application of 1 μM ATP (Sigma, St Louis, MO). Data acquisition and processing were performed using LAXS software. Regions of interest across the field of view were selected and the average pixel intensity in each frame was measured. Data were plotted as the ratio of fluorescence intensity versus time and then converted to a relative scale.
[0125] Immunoprecipitation: 50 μl of magnetic beads (Invitrogen) were incubated with 1 μg of pITPR1 antibody for 45 min at 4°C. The supernatant was discarded and the beads were washed with binding buffer. 200-400 μg of sample protein was added and incubated with the beads for 4 h at 4°C. The protein complexes were then washed three times with wash buffer and eluted with SDS sample buffer. The samples were then heated at 70°C for 10 min and subjected to Western blot analysis for Car10. The methods described herein are also suitable for use with Car8, CA8, CA8 fragment (CA8-204), CA10, Car11 and CA11.
[0126] Immunohistochemistry (IHC): HEK293 cells were seeded on poly-L-lysine / laminin-coated coverslips at a density of 1 per coverslip, and after 24 hours, cells were transfected with Car10, CA10, or empty vector, respectively. Cells were cultured for an additional 96 hours at 37°C, then treated with 1 μM forskolin (F6886 Sigma, St. Louis, MO) for 5 minutes, then fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton® X-100 for 10 minutes, and blocked with 1% bovine serum albumin (BSA, Sigma) for 1 hour. The cells were then incubated overnight at 4° C. with anti-pITPR1 (catalog number 8548s cell signaling technology), anti-Car10 (catalog number SAB1102286 Sigma, St Louis, MO), anti-V5 (catalog number R960 Invitrogen), anti-ITPR1 (catalog number 8568 Cell Signaling technology) antibodies. The next day, the cells were incubated with the corresponding secondary antibodies (1:200) for 1 hour at room temperature in the dark. The coverslips were dried and mounted on slides using fluorescent mounting medium with Dapi (catalog number P36931 Life Technologies). It will be understood that IHC methods using anti-Car8, anti-CA8, anti-CA8 fragment (CA8-204), anti-CA10, anti-Car11 and anti-CA11 antibodies are also contemplated.
[0127] Statistical analysis: Data are expressed as mean ± standard error of the mean (SEM) and analyzed for statistical significance by Student's t-test for two-group comparisons, one-way ANOVA with Bonferroni's post-hoc test for multiple comparisons with one variance (more than two groups), and two-way ANOVA with Bonferroni's post-hoc test for multiple comparisons with two variances (more than two groups). All data analyses and graphics were performed using GraphPad Prism 5.0 software (GraphPad Inc, San Diego, CA).
[0128] Pharmacodynamics: Bioassay of the impact of the electrophysiological properties of the viral constructs (verification of the reduction of neuronal excitability in vitro): Neurons and other transfected cells are tested in a current-clamp perforated whole-cell setup of the patch-clamp technique, at room temperature (20-25 °C). Perforation is obtained by amphotericin B to ensure adequate current-clamp recordings while at the same time maintaining intact cytosolic calcium concentrations and adequate cytosolic signaling apparatus in each cell population that is to be tested. Pull and polish patch micropipettes (resistance values 3-6 M) as previously described. Sarantopoulos C,et al.,J Neurosci Methods.2004;139(1):61-8, Sarantopoulos C,et al.,Reg Anesth Pain Med.2002;27(1):47-57, Kawano T,et al.,Mol Pain.2009;5:12, Sarantopoulos CD,et al.,Brain Res.2007;1132(1):84-99, Hogan QH,et al.,Pain.2000;86(1-2):43-53. For recording, a Multiclamp 700B amplifier was used (Axon Instruments,Foster,CA,USA) and the signal was digitized using a converter (DigiData1440A;Axon Instruments). For analysis, pCLAMP software (Axon Instruments) was used. Whole-cell current-clamp recordings are performed using extracellular Tyrode's solution and internal pipette solution as described previously. Excitability parameters are compared between groups of cells categorized by expression parameters. Recordings from cell populations differing in expression patterns (e.g., positive and negative TrkA or Nav1.8), size (large vs. small DRG somatosensory neurons), and excitability will vary depending on the viral vector used. The following parameters are compared between groups: (1) resting membrane potential (RMP) and spontaneous electrical activity (number of spontaneous action potentials (AP) (spikes / min)) recorded for at least 3 min at baseline. After stable recordings are established for at least 1 min, determine the RMP for further comparisons.Neurons with resting potentials more depolarized than -45 mV are rejected because they show large leakage currents. (2) APs are elicited in response to suprathreshold stimulation by current injection. The current threshold is determined by sequential 25 pA step increments until a monomorphic AP is evoked, and each threshold will be recorded. APs are then elicited by a single >2 ms threshold current pulse and captured in a subsequent recording lasting 500 ms (to measure both AP and afterhyperpolarization (AHP) parameters). (3) AP characteristics are measured and compared between groups, including RMP, peak AP amplitude, AP threshold, and AP duration at threshold, as well as at 5% and 50% amplitude. AP threshold is measured at the onset of the depolarization phase surge. APs are also measured from the point where a horizontal time series line is drawn from this AP threshold to the point where the descending repolarization phase crosses this line. AP amplitude is measured from the RMP to the AP peak. AP duration is determined at the midpoint of 5% voltage from RMP to AP peak and 50% voltage from RMP to peak. AP magnitude is expressed as area under the curve. AHP amplitude is measured from RMP to the most hyperpolarized level of the AHP phase. AHP duration is measured at points representing 50% and 90% recovery to RMP. AHP magnitude is expressed as area under the curve. Two other measures of cell excitability are used, including rheobase (determined as a series of incrementally increasing minimum current amplitudes of the depolarizing 200 ms pulse that elicits an AP) and a pattern of AP spiking during the current injection step that is at least twice as long as that of the rheobase, where the cell either produces a single AP or fires repeatedly.
[0129] The HSV TrkA and Nav1.8 promoters drive robust long-term reporter expression: the virus only reaches the DRG cell body via retrograde transport in vitro. Because these are rdHSV, they cannot infect nearby neuroglial cells, or other DRG cells that do not project to the local injection site. After more than 30 days, we observe strong expression from both the LAT locus and the ICP4 locus in rodents. The ICP4 locus was chosen as the site for expression cassettes (TrkAp-CA, Nav1.8p-CA, Advillinp-CA, etc.) because it increases over time. For example, if sufficient expression in neurons is not demonstrated or expression decreases over time, the expression cassette can be relocated to the LAT locus.
[0130] Pharmacokinetics: Dose-response and tissue specificity (in vivo structural and functional validation): Analgesia and motor function tests include measurements of mechanical pain (von Frey), thermal pain (Hargreaves), and non-reflex sensory and motor function (measurement of spontaneous wheel running using automated measurements: wheel running distance / time, wheel running time, and stride distance). Eighteen naive male C57BL / 6J mice per assay condition are used. The initial time course of analgesic response is monitored every other day until 14 days, then weekly until 28 days (end of life). Clinical safety assessments are performed at baseline and weekly for each mouse (e.g., body weight, general appearance, food consumption, blood pressure, temperature). Restricted neuronal expression is assessed similarly to these preliminary studies in skin, peripheral nerve, DRG, and dorsal horn (DH) using qPCR (local) and immunohistochemistry (IHC) (cell subtypes).
[0131] Evaluation of routes of administration: In various embodiments, the expression vector is administered via direct sciatic and femoral nerve (SFN) or intra-articular (IA) injection. The biological responses achieved using these routes are compared to those achieved using intradermal administration. Direct sciatic nerve injection achieves significant analgesia with induction of lumbar DRG. The sensory innervation of major joints is accessible via direct IA injection. DRG induction is achieved using this approach, providing rapid adoption by clinical experts, ease of access, and potentially adequate viral infectivity of all disease-affected dermatomes. Direct peripheral nerve block with radiofrequency ablation is easily achieved as an alternative using conventional techniques for some major joints (e.g., knee via genu block, shoulder via suprascapular nerve block), and peripheral nerve block for pain relief of other joints is not infeasible (e.g., temporomandibular joint, hip, ankle, elbow, wrist, etc.). Currently, options for treating temporomandibular joint (TMJ) pain are very limited, and intra-articular injection of the expression vector described herein represents a transformational therapy for symptom control.
[0132] All measurements are individual, masked to treatment. Animals are randomly assigned to groups. Assays are performed at approximately the same time on the day. Periodic clinical safety assessments are performed (e.g., body weight, general appearance, food consumption, pulse, blood pressure, temperature). The highest attainable dose (PFU) is used for injection into SFN and IA as well as a series of dilutions (up to 10,000 fold) to optimize subsequent parameters for all expression vectors. 18 naive male C57BL / 6J mice / group are used. Analgesic responses are monitored every other day until 14 days and then weekly until 28 days (end of life) (analgesia, hyperalgesia suppression to mechanical and heat-evoked responses, automated voluntary running wheel (wheel running distance / time, wheel running time, wheel running speed, stride)). Additionally, baseline and weekly clinical safety assessments are performed on each mouse (e.g., body weight, general appearance, food consumption, blood pressure, body temperature, etc.). Restriction of neuronal expression is assessed in peripheral nerves, DRG and DH using QPCR (local) and IHC (cell subtypes using dual staining). Alternatively, direct DRG transfer can be achieved using transforaminal epidural injections.
[0133] Pharmacodynamics: Analgesia and Antihyperalgesia Bioassays: Both chronic inflammatory and chronic neuropathic pain models will be employed. These studies include protection (prevention) trials for CFA (expression vector injected prior to pain), and protection and treatment trials for SNL and OA (expression vector injected after nerve injury occurs and assessed over time). Direct sciatic nerve injections prevent and treat chronic neuropathic pain in the SNL model (see Figure 7). Preliminary short and long term safety studies related to mechanism and off-target toxicity can be performed in the two models. All measurements are individual recorded masked to treatment. Animals will be randomly assigned to groups. Assays will be performed at approximately the same time of day. Clinical pathology, visual examination, organ weights, and histopathology will be evaluated, and CA8, CA8-204, CA10, CA11, ITPR1, pITPR1 will be measured using DRG, spinal cord, CSF, and blood. Consider apoptosis of DRG neurons and glia. In addition to efficacy assessment, perform clinical safety assessments (e.g., body weight, general appearance, food intake, blood pressure, temperature). Adopt a "treat" design whenever possible based on the time course of response. Direct nerve "block" approaches are potentially applicable to a variety of pain disorders, including chronic headache, trigeminal neuralgia, and other craniofacial pain disorders. If desired, modify pathways based on the specific model and potential clinical application. For example, the IA pathway is particularly associated with TMJD. As this technique is difficult in mice, the knee OA model can be adopted as a surrogate, since it is both feasible and a chronic, widely recognized clinical condition. Progressive OA, like TMJD, can cause rest pain (i.e., spontaneous or neuropathic pain) that is generally resistant to nonsteroidal anti-inflammatory drugs (NSAIDs) and is therefore characterized by both neuropathic and nociceptive pain. Useful in this regard is the well-established monosodium iodoacetate (MIA) intra-articular injection model of OA, which elicits joint osteolysis, cartilage erosion, and weight-bearing asymmetry with associated tactile and thermal hypersensitivity in mice.It has previously been shown that spontaneous pain is not relieved by diclofenac, TRPV1 and TRPA1 antagonists, but is fully relieved by intra-articular lidocaine in this model, and IA injection of an expression vector mediating Nav1.8-specific LALA (Nav is the target of lidocaine and other short-acting local anesthetics) would be effective in this model.
[0134] Promoters: Promoter sequences useful in the context of the studies described herein include, but are not limited to, TrkB, TrkC, Nav1.9, other Nav gene promoters, NMDA promoter, advillin, CGRP, 5HT, NK1, ASIC3, NPY or NF200 to drive expression of CA expression sequences including CA8, CA8 fragments (such as CA8-204), CA10, CA11, and non-human orthologs including Car8, Car10 and Car11.
[0135] result Overexpression of V5-Car10 and V5-CA10 proteins inhibits forskolin-induced pITPR1 in vitro. The results described herein demonstrate the use of a pharmacodynamic bioassay to examine the effect of Car10 on regulating the activation of ITPR1 (pITPR1) by phosphorylation, for example, which enhances the response of ITPR1 to IP3 ligands. HEK293 cells were transfected with AAV8-V5 vectors overexpressing Car10 and CA10, an empty vector, and vehicle as a control. To distinguish between exogenous and endogenous CA10 / Car10 expression, the V5 sequence was inserted into the C-terminal region of Car10 or CA10. Western blot analysis demonstrated that forskolin increased pITPR1 levels in a dose-dependent manner (Figure 1A). The V5 tag was used to detect protein overexpression after transfection of V5-Car10 and V5-CA10 vectors (Figure 1B). Overexpression of Car10 and CA10 reduced forskolin-induced ITPR1 phosphorylation in HEK293 cells, whereas empty vector did not alter ITPR1 phosphorylation ( Fig. 1C ).
[0136] Using IHC, we observed an increase in pITPR1 in HEK293 cells in response to 1 μM forskolin after transfection with empty vector (AAV-none), but no increase in pITPR1 after transfection with V5-Car10 and V5-CA10. These data demonstrate that Car10 and CA10 are sufficient to inhibit phosphorylation of the regulatory domain at Ser-1755 in HEK293 cells and are critical for ITPR1 activation and IP3-induced calcium release.
[0137] Overexpression of V5-Car10 and V5-CA10 inhibits ATP-induced free calcium release in vitro: ITPR1 contains functionally distinct domains, including a "regulatory" domain that responds to intracellular regulators such as calcium, calmodulin, ATP, and carbonic anhydrase 8 (Car8). ATP increases ITPR1-dependent calcium release by increasing the open probability of the channel in the presence of activating concentrations of IP3 and calcium. Binding to this regulatory domain is thought to be required for Car8-mediated inhibition of ITPR1 activation and ATP-mediated calcium release. Therefore, we examined the ability of CA8 fragments (e.g., CA8-204), Car10, and CA10 to bind ITPR1 and pITPR1. Co-immunoprecipitation of each protein with antibodies against the V5 tag containing ITPR1 and pITPR1 was performed before and after forskolin stimulation of HEK293 cells. Western blotting shows that CA8-204, Car10, and CA10 do not bind to ITPR1. Surprisingly, functional bioassays assessing ITPR1 activation (e.g., pITPR1) showed that all of these unbound proteins inhibited ITPR1 activation by co-immunoprecipitation of these proteins, indicating a reduction in pITPR1.
[0138] To further explore whether overexpression of FLAG-CA8-204 (data not shown), V5-Car10 and V5-CA10 could inhibit ATP-induced calcium release, HEK293 cells were infected with each of these constructs and real-time intracellular calcium concentrations were measured at baseline and in response to ATP stimulation (Figure 2). ATP stimulated calcium release and increased cytosolic free calcium levels in a dose-dependent manner. Cytosolic free calcium levels after AAV-none transfection increased in response to 1 μM ATP compared to baseline in HEK293 cells. In contrast, free calcium concentrations did not change in response to 1 μM ATP after transfection with AAV-FLAG-CA8-204, AAV-V5-Car10 and AAV-V5-CA10 compared to baseline and AAV-V5-CA8. These data demonstrate that CA8-204, Car10 and CA10 can inhibit the activation of ITPR1, thereby reducing ATP-stimulated cytoplasmic free calcium levels in these cells.
[0139] Car10 and CA10 sciatic nerve gene therapy produces analgesia and suppresses inflammatory pain behavior: AAV8-V5-Car10 and AAV8-V5-CA10 both produce analgesia (increased thermal latency from baseline) after sciatic nerve injection in C57BL / 6 mice compared to controls up to 15 days after injection. Intraplantar injection of carrageenan 16 days after (after thermal testing) produced acute thermal hypersensitivity in saline and AAV8-no control groups at 17 and 18 days after injection. However, both AAV8-V5-Car10 and AAV8-V5-CA10 did not show hypersensitivity after carrageenan injection 16 days after injection (thermal latency below baseline). Analgesia recurred in both AAV8-V5-Car10 and AAV8-V5-CA10 groups after 18 days and was maintained up to 27 days after injection. No similar findings were observed in the control groups. Please refer to Figure 3.
[0140] Similarly, both AAV8-V5-Car10 and AAV8-V5-CA10 produce analgesia after sciatic nerve injection in C57BL / 6 mice compared to controls (increased thermal latency from baseline) up to 15 days after virus injection in a complete Freund's adjuvant (CFA) chronic inflammatory pain mouse model. Intraplantar injection of CFA 16 days later (after thermal testing) produced acute thermal hypersensitivity in all groups after 17-19 days. Both AAV8-V5-Car10 and AAV8-V5-CA10 groups appeared to recover by 24 days and demonstrated analgesia up to 34 days later, similar to that observed 16 days after pre-CFA injection. See Figure 4.
[0141] Car10 Gene Therapy Produces Analgesia and Suppresses Neuropathic Pain Behavior: The effect of administration of the disclosed viral vector in preventing neuropathic pain was examined using the Chung mouse model. Chaplan et al., J Neurosci Methods. 1994; 53(1): 55-63. AAV8-V5-Car10 produced an analgesic response at mechanical withdrawal thresholds after 12 to 22 days, despite spinal nerve ligation after 19 days. There was no similar increase in withdrawal threshold in any of the other groups (Figure 5).
[0142] Consideration The data described herein demonstrate for the first time that (1) overexpression of CA8 fragment (CA8-204), CA10, and Car10 proteins in vitro inhibits phosphorylation of the regulatory domain of ITPR1 at Ser-1755 in response to forskolin, (2) overexpression of CA8 fragment (CA8-204), CA10, and Car10 inhibits ATP-stimulated intracellular calcium release in vitro, and (3) gene transfer of AAV8-V5-CA10 and AAV8-V5-Car10 into nociceptors via sciatic nerve injection in C57BL / 6J mice produces significant analgesia and prevents hyperalgesia inhibition using inflammatory and neuropathic pain models. These findings establish for the first time that CA8 fragment (CA8-204), CA10, and Car10 regulate the ITPR1 cytosolic free calcium signaling pathway, which is important for nociception and pain.
[0143] CA10 may be involved in other functions, including chondrocyte regulation. Loss of CA10 expression could potentially lead to the formation of chondroblastomas via dysregulation of the ITPR1 cytosolic free calcium signaling pathway. Therefore, treatment of chondroblastomas could be obtained by overexpression of CA10, CA8, or CA8 fragments using viral vectors.
[0144] Osteoarthritis (OA) is characterized by cartilage deterioration. Akkiraju et al.,J Dev Biol.2015;3(4):177-192. Also interestingly, a recent genome-wide association between copy number variants (CNVs) and OA susceptibility in a Korean population demonstrated a strong association between OA and CA10. Moon et al.,BMC Musculoskelet Disord.2015;16:76. Furthermore, Mori et al. described a genetic association between single nucleotide polymorphisms in CA8 and CA10 and bone mineral density (BMD) of the vertebrae and femur associated with osteoporosis in Japanese women. Mori et al.,J Bone Miner Metab.2009;27(2):213-216. These researchers suggested that genetic variants at the CA8 and CA10 loci may be important determinants of osteoporosis in these and potentially other women. If these associations hold true in the broader population, it would be reasonable to examine whether functional variants at the CA8 and CA10 loci are associated with OA disease severity, pain, and disability. Moreover, it seems pertinent to examine the role of the ITPR1 cytosolic free calcium signaling pathway and whether functional variants of CA8, CA10, and CA11 may differentially affect ITPR1-mediated calcium release in regulating osteoclasts and chondrocytes, thereby differentially impacting osteoporosis and osteoarthritis.
[0145] Finally, mental health disorders often coexist with chronic pain. Trinucleotide repeat expansions have been associated with heritability in fragile X syndrome, Huntington's disease, myotonic dystrophy, and spinocerebellar ataxia. Akkiraju et al.,J Dev Biol.2015;3(4):177-192. In addition, unstable repeats have also been implicated in schizophrenia and bipolar disorder. Vincent et al.,Psychiatr Genet.2016;26(4):156-165. Subsequent studies have shown that much of the signal for psychiatric illness originates from three regions with large repeats on chromosomes 13q21.33, 17q21.33-q22, and 18q21.2. The 17q trinucleotide expansion is within an intron of the CA10 gene. Vincent et al., supra; Ikeuchi et al., Genomics. 1998;49(2):321-326. In light of the new potential roles for CA10 described herein, it is worth reexamining the relationship between this unstable trinucleotide repeat and loss of function due to functional variants of CA10, including osteoarthritis, osteoporosis, and chronic pain conditions, and the use of CA10 overexpression in these affected individuals using the compositions and methods described herein to treat these disorders.
[0146] In summary, this example demonstrates the utility of PK / PD bioassays and animal models of viral vectors encoding CA8, CA8 fragment (CA8-204) fragment, and CA10 for treating pain, as well as routes of administration. In particular, these data establish that the materials and methods described herein produce analgesia and suppress both inflammatory and neuropathic pain.
[0147] Example 2 The following examples are provided by using adeno-associated viral vectors encoding the CA8 fragments described herein (AAV8-FLAG-CA8 204C (CA8 204C ) and AAV8-flag-CA8 204G (CA8 204GWe demonstrate that administration of ) produces analgesia and antihyperalgesia in a clinically relevant animal model, the carrageenan inflammatory pain model.
[0148] pAAV-flag-CA8-204 G (ALT G) and pAAV-flag-CA8-204 C Construction of (ALT C). Primers containing SalI and KpnI sites were designed to construct the full-length alternative splice variant (CA8-204) with either "G" or "C" at SNP rs6471859. The pAAV-MCS expression construct is shown on the right (vector map on the right). See Figure 39.
[0149] Paw withdrawal latencies were measured at baseline and on various days after viral vector administration (sciatic nerve injection (SN)) and / or carrageenan injection (left paw). Seven days after administration, AAV8-FLAG-CA8 204C (CA8 204C ) or AAV8-FLAG-CA8 204G (CA8 204G Mice (n = 8 per group) received SN injections of 1.5 μl, 1 × 10 13 AAV8-V5-CA8 WT (CA8 WT) (positive control) and AAV8-V5-CA8 MT (CA8 mutant) (negative control) mice administered the viral vector showed increased paw withdrawal latency compared to mice administered the AAV8-V5-CA8 WT (CA8 WT) (positive control) and AAV8-V5-CA8 MT (CA8 mutant) (negative control). After receiving carrageenan injections 15 days after viral vector administration, mice in the CA8 MT (negative control) group showed significantly reduced paw withdrawal after 16–18 days, indicating a failure to recover from carrageenan-induced inflammatory pain. However, CA8 WT, CA8 204G , CA8 204C Both groups of mice demonstrated enhanced paw withdrawal latencies, with CA8 WT and CA8 204G , CA8 204C (N=8, **** P<0.0001 *** P<0.001, 2-way ANOVA statistical group test GraphPad). See Figures 31 and 32.
[0150] Example 3 This example demonstrates that CA10 binds to RYR and pRYR, as demonstrated by co-immunoprecipitation. NBL cells were transfected with AAV-V5-CA10 and AAV-V5-Car10 using lipofectamine (LTX). Cellular proteins were extracted 48 hours after transfection.
[0151] Immunoprecipitation (IP) and Western blotting (WB) were utilized to detect binding. Rabbit anti-RYR1 was used for IP and chicken anti-V5 was used for WB analysis. Approximately 1 / 10 of the IP protein was used for WB to show V5-labeled CA10 or Car10 in WB. B-actin was used as a loading control. See Figure 33, which establishes the co-immunoprecipitation of CA33 with RYR. Similar results were obtained with CA10 and ITPR1.
[0152] These data also suggest for the first time that CA10 may possibly regulate RYR-dependent calcium release via binding to RYR1 and RYR3.
[0153] Example 4 This example demonstrates that overexpression of V5-CA10 protein inhibits forskolin-induced pITPR1 in vitro.
[0154] To investigate the role of CA10 in regulating ITPR1 phosphorylation (pITPR1), which enhances the response of ITPR1 to IP3 ligands, HEK293 cells were transfected with AAV8-V5-CA10 vector. Transfection with empty vector or application of vehicle served as controls. To distinguish between exogenous and endogenous expression of intact protein in tissues or cell lines, the V5 sequence was inserted into the C-terminal region of CA10. Cells were stained with DAPI or pITPR1 for nuclei and fused.
[0155] Using the V5 tag, protein overexpression after transfection of AAV-V5-CA10 (and mouse V5-Car10 coding vector) was observed using Western blot analysis (Figure 34A). Overexpression of CA10 and Car10 reduced forskolin-induced ITPR1 phosphorylation in HEK293 cells, whereas empty vector did not change pITPR1 levels (Figure 34B). These experiments show that overexpression of CA10 (and mouse Car10) in NBL cells in vitro inhibits phosphorylation of the regulatory domain of ITPR1 at Ser-1755 in response to forskolin.
[0156] Example 5 The following example demonstrates that overexpression of CA10 inhibits ITPR1 and RYR-mediated calcium release in response to pain mediators.Surprisingly, the study described herein demonstrates that 5HT-mediated RYR-dependent calcium release is almost completely inhibited by ryanodine in NBL cells.Moreover, it is also observed that overexpression of V5-CA10 in NBL cells inhibits 5HT-mediated calcium release.Therefore, it seems that 5HT-mediated signaling in NBL cells is mainly via RYR.
[0157] Next, overexpression of V5-Car10 and V5-CA10 in HEK293 cells was found to inhibit ATP-induced cytoplasmic calcium release. Fura2 calcium imaging data demonstrated that overexpression of Car10 and CA10 proteins inhibited ITPR1-mediated cytoplasmic calcium release to 1 μM ATP in HEK293 cells when compared to empty vector controls (P<0.001). (N=4 coverslips and a total of 200 cells per sample) ** P < 0.01, *** P<0.001 by two-way ANOVA followed by Bonferroni test.) See FIG.
[0158] We also found that 5HT-induced RYR-dependent calcium release in NBL cells was inhibited by ryanodine. Fura2 calcium imaging data demonstrated that 50 μM 5HT-induced cytoplasmic calcium release in NBL cells was significantly inhibited by ryanodine in a dose-dependent manner when compared to vehicle control (P<0.001). (N=4 coverslips and a total of 200 cells per sample) ** P < 0.01, *** P<0.001 by two-way ANOVA followed by Bonferroni test). See FIG.
[0159] These findings suggest that CA10 regulates the ITPR1 cytosolic free calcium signaling pathway that is important for nociception and pain behavior. Furthermore, the present data show that 5HT stimulates calcium release that is almost completely inhibited by ryanodine, suggesting that serotonin, but not ITPR1, mediates calcium release via RYR.
[0160] Next, overexpression of V5-Car10 and V5-CA10 in NBL cells was found to inhibit 50 μM 5HT-induced cytoplasmic calcium release. See FIG. 37. Fura2 calcium imaging data demonstrated that 50 μM 5HT-induced cytoplasmic calcium release in NBL cells was almost completely inhibited by 10 nM ryanodine when compared to the vehicle control (P<0.001). Furthermore, 5HT-induced cytoplasmic calcium release in NBL cells was also inhibited by overexpression of V5-Car10 and V5-CA10 proteins in NBL cells when compared to the empty vector control (P<0.001). (N=4 coverslips and a total of 200 cells per sample) ** P < 0.01, *** P < 0.001 by two-way ANOVA followed by Bonferroni test).
[0161] Example 6 pCMV-N-flag-CA8-204 G and pCMV N-flag-CA8-204 CPrimers containing SalI and KpnI sites were designed to construct a full-length alternative variant (CA8-204) with a "G" at the rs6471859 SNP into the pCMV-N-flag vector (Clontech). Site-directed mutagenesis (Invitrogen) was used to generate pCMV-N-flag-CA8-204, which generates a novel fragment ending in exon 3 with the "C" allele at rs647859. C was constructed. See Figure 38.
[0162] CA8-204 in calcium release in HEK293 cells G Inhibition (Ca 2+ Fura2 image analysis). pCMV-N-flag-CA8-204 G (1,695bp), pCMV-N-flag-CA8-204 C , AAV2-V5-CA8 WT (positive control), or empty vector (negative control). (n=6, number of coverslips per experiment, number of experiments=3, P value<0.001, comparisons between the three groups were performed by Tukey's multiple comparison test (GraphPad Prism Software). See Figure 40.
[0163] Differential tissue expression of CA8 ALT(G) and CA8 ALT(C) in HEK293 and NBL cells. Quantitative RT-PCR (Real-time PCR, Applied Biosystems) from (a) HEK293 cells and (b) neuronal cells (NBL) after transfection with alternative variants pCMV-FLAG-N CA8 ALTG (bp 1417 of CA8-204) or pCMV-FLAG-N CA8 ALTC ("C" allele of rs6471859) carrying the "G" allele at rs6471859. The amount of each vector was normalized using the beta-actin (ACTB) gene product. The primers used were designed to cover the 3'UTR region of CA8-204. HK cells do not express detectable CA8-002 transcripts carrying the C genotype of variant rs6471859. N = 3, number of experiments = 3 (Statistical analysis was performed using GraphPad Prism Software. ** = p-value < 0.001, *** = p-value <0.0001, one-way ANOVA was applied followed by Tukey group comparison. See Figures 41A and 41B.
[0164] CA8-204 C and CA8-204 G The fragments show varying tissue expression. CA8-204 in HEK 293 (non-neuronal cells) and NBL (neuronal cells) C and CA8-204 G The vectors expressing the transcripts were transfected and subjected to quantitative RT-PCR (QPCR) (Applied Biosystems) using SyBr Green (AB) and normalized using beta-actin as an internal control. Primers were set to CA8-204, which is selectively expressed in these cell lines. C and CA8-204 G The inventors designed the CA8-204 fragment to flank the 3'UTR region of the CA8-204 sequence, consistent with cell-specific splicing factors directing the expression of each fragment. C is expressed primarily in NBL cells, and CA8-204 GWe observe striking differences in CA8 fragment splicing and expression, which is primarily expressed in HEK293 cells. (N=4, *** P value <0.001, one-way ANOVA was applied followed by Tukey's post-hoc test). See Figure 42.
[0165] CA8-204 C The fragment inhibits ATP-stimulated calcium release in NBL cells. C Cells were transfected with vectors carrying nucleotide inserts expressing CA8-201 (CA8 wild-type positive control) or empty vector (negative control) and subjected to calcium imaging analysis (Fura2, Leica Micro Systems) using 1 μM ATP as a stimulant for intracellular calcium release. C and CA8-201, Ca expression levels in NBL cells in vitro 2+ It was possible to inhibit the release of CA8-204. C Inhibition of calcium release by CA8-201 exceeded that of CA8-201 (wild-type full-length transcript / peptide). In contrast, empty vector (negative control) failed to inhibit calcium release in this assay. (N=6, *** *P<0.001, statistical analysis by one-way ANOVA, group comparison via Tukey's post-hoc test, GraphPad Prism). See Figure 43.
[0166] CA8-204 G or CA8-204 C The peptide fragments are 28 kDa or 26 kDa, which are selectively expressed in HEK293 cells or NBL cells. G , flag-CA8-204 C Extracts from HEK293 cells (center) or NBL cells (right) transfected with vectors expressing either CA8, V5-CA8-201 (wild-type full-length CA8) transcripts were run on the same gel and immunoblotted with either anti-flag or anti-V5 antibodies. In HEK293 cells, flag-CA8-204 at 28 kDa was detected. GOnly peptide fragments were detected, and flag-CA8-204 was detected at 26 kDA in NBL cells. C Only peptide fragments were detected. Data were merged after immunoblotting. Data were normalized to beta-actin (control). See Figure 44.
[0167] CA8 204 C inhibits forskolin-induced phosphorylation of pITPR1. WT , CA8 204 C Or vector containing empty vector (vehicle) was transfected. Vehicle was used as a negative control. Data was normalized to vinculin as an internal control. See Figure 45.
[0168] All publications, patents, and patent applications mentioned in this specification are incorporated by reference herein as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, it will be readily apparent to those skilled in the art that certain changes and modifications thereto can be made in light of the teachings of the invention without departing from the spirit or scope of the appended claims.
Claims
1. A pharmaceutical composition for treating or preventing pain in a subject in need thereof, comprising an expression vector comprising a nucleic acid sequence encoding a fragment of carbonic anhydrase 8 (CA8), the expression vector being designed to be expressed in the subject to produce the CA8 fragment, and the nucleic acid encoding the CA8 fragment has the nucleic acid sequence of SEQ ID NO:34 (CA8-202), SEQ ID NO:13 (CA8-204), SEQ ID NO:32 (CA8-204C), or SEQ ID NO:33 (CA8-204G).
2. The pharmaceutical composition of claim 1 , wherein the expression vector is a viral vector.
3. The pharmaceutical composition according to claim 2 , wherein the viral vector is an adeno-associated viral vector or a herpes simplex viral vector.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the nucleic acid sequence encoding the fragment of carbonic anhydrase 8 is operably linked to a promoter selected from the group consisting of CMV promoter, TrkA promoter, TrkB promoter, TrkC promoter, Nav1.9 promoter, Nav1.7 promoter, Nav1.8 promoter, NMDA promoter, advillin promoter, CGRP promoter, 5HT promoter, NK1 promoter, ASIC3 promoter, NPY promoter, and NF200 promoter.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pain is neuropathic pain, nociceptive pain, or inflammatory pain.
6. 5, wherein the pharmaceutical composition comprises: (a) administering to the dorsal root ganglion of said subject; (b) administering the expression vector via intra-articular injection; (c) orally administering the expression vector; (d) administering the expression vector to the trigeminal ganglion; (e) administering the expression vector via peripheral nerve injection; (f) administering the expression vector via a catheter to the site of pain; (g) administering the expression vector via a needle to the site of pain; The pharmaceutical composition according to any one of claims 1 to 4,
7. The pharmaceutical composition according to any one of claims 1 to 4, comprising the use of image analysis for administering the expression vector.
8. The pharmaceutical composition of claim 1, wherein the fragment of carbonic anhydrase 8 has the amino acid sequence of SEQ ID NO: 30 (CA8-204C) or SEQ ID NO: 31 (CA8-204G).
